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Background: Vitamin D is a fat-soluble vitamin with important functions in several 
different tissues, and poor vitamin D status has been found to be associated with chronic 
diseases like type 1 diabetes, metabolic syndrome, cardiovascular disease, infectious 
diseases, and several forms of cancer. Different modifiable and non-modifiable factors 
have been suggested to be associated with serum 25(OH)D levels. The prevalence of 
insufficient serum 25(OH)D level is high, and determinants of vitamin D status are not 
fully elucidated. The main purpose of this thesis was to explore factors associated with 
circulating vitamin D levels which could contribute to a better understanding of 
potential causes of vitamin D deficiency. 
 
Methods: This was a cross-sectional study of 4118 patients who underwent coronary 
angiography at Haukeland University Hospital or Stavanger University Hospital with 
suspected or verified stable angina pectoris (SAP) and available data on 25(OH)D serum 
concentrations. To assess the relationship between serum 25(OH)D and dietary, clinical, 
and biochemical variables measured in the two cohort studies, linear regression was 
used, while quantile regression analyses were conducted to assess the relationships 
between 25(OH)D status and the same variables in selected quantiles of 25(OH)D levels. 
To estimate the strength of the linear relationships between serum 25(OH)D levels and 
the measured predictors on a standardized scale, Spearman`s rank correlation 
coefficients, rhos, were calculated.  
 
Results: The results showed that serum 25(OH)D levels were positively associated with 
blood sampling during the summer months and vitamin D intake through diet, fish, and 
egg consumption, and with circulating concentrations of HDL cholesterol (HDL-C), 
riboflavin, pyridoxal phosphate (PLP), pyridoxic acid (PA), folate, cobalamin, vitamin A, 
vitamin E, choline, and sarcosine. Negative associations were found for blood sampling 
during the winter season and body mass index (BMI), with circulating concentrations of 
triglycerides (TGs), blood glucose, and hemoglobin A1c (HbA1C), and with total 
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homocysteine (tHcy), dimethylglycine (DMG), and C-reactive protein (CRP) levels at low 
serum 25(OH)D concentrations. 
 
Conclusions: In this cross-sectional study, we found that serum 25(OH)D levels were 
associated with seasonality, vitamin D intake, and BMI, and with circulating levels of 
HDL-C, TGs, PLP, vitamin A, and vitamin E, total homocysteine, as well as markers of 
glucose metabolism. These results may motivate future experimental studies further 
investigating determinants of vitamin D status and their mechanistic relationships, 
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1  Introduction 
Vitamin D, calciferol, is a fat soluble vitamin essential for calcium and phosphorus 
metabolism, and insufficient levels of vitamin D are known to be detrimental to bone 
health (1,2). Several functions besides calcium and phosphorus metabolism have been 
discovered, and poor vitamin D status has been found to be associated with chronic 
diseases like type 1 diabetes, metabolic syndrome, cardiovascular disease (CVD), 
infectious diseases, and several forms of cancer (1,3–5). A high global prevalence of 
insufficient vitamin D levels increases the risk of health consequences in a large group of 
people (3,4). Different factors have been suggested to be associated with circulating 
levels of vitamin D (6–8), but potential determinants of vitamin D status have not been 
fully elucidated. The main aim of this thesis was to investigate relationships between 
serum levels of vitamin D and dietary, clinical, and biochemical variables measured in a 
large cohort.   
  
1.1 Vitamin D 
1.1.1 The “sunshine” vitamin 
Lack of sunlight has historically been strongly associated with the skeletal disease 
rickets (1,2). Early in the 1900s, it was suggested that rickets was caused by a dietary 
deficiency, and animal studies showed that the supply of cod liver oil prevented and 
cured the disease, and this resulted in the discovery of vitamin D as an essential nutrient 
(1,2).  
 
The observed connection between sunlight exposure, vitamin D, and the development of 
rickets led to the identification of the two precursors of vitamin D, named 7-
dehydrocholesterol (7-DHC) and ergosterol (1,2,9). 7-DHC is a sterol produced by 
animals, while ergosterol is found in plants, and both of these precursors change 
structure when exposed to ultraviolet irradiation from sunlight (1,2,9). When exposed to 
ultraviolet irradiation, 7-DHC is transformed into the provitamin D called vitamin D3 or 
cholecalciferol, while ergosterol is transformed into ergocalciferol, also called vitamin D2 
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(1,2,9). Because of the importance of sunlight exposure in the synthesis of vitamin D, the 
vitamin is also called the “sunshine vitamin” (1,2,9).  
 
1.1.2 Vitamin D metabolism 
7-DHC in the epidermis of the skin absorbs UV-radiation between 290 nm and 315 nm, 
causing an isomerization that involves photolytic ring opening to produce the 9,10-seco-
sterol previtamin D3 (1,9,10). Previtamin D3 has the thermodynamically unstable s-cis, s-
cis conformation and is easily transformed to vitamin D3 through a non-enzymatic heat-
induced isomerization, which cause the hydrophilic and hydrophobic interactions 
between the previtamin D3 and the membrane fatty acids to break, and vitamin D3 is 
released from the skin cell membrane into the blood (1,2,10). If the production of 
vitamin D3 is high and the serum levels are above required, some of the vitamin D3 can 
be stored in the fat tissue and be released in periods with insufficient synthesis 
(1,11,12).  
 
Vitamin D2 and D3 have to be further activated before the vitamin can perform its 
functions in the target tissues (2,9). The vitamin D3 produced in the skin or ingested 
through the diet is transported in the blood bound to vitamin D-binding protein (DBP) 
or incorporated into chylomicrons, and delivered to the liver where vitamin D3 is 
converted to 25-hydroxyvitamin D3 (25(OH)D) by the vitamin D 25-hydroxylase CYP2R1 
(1,2). 25(OH)D3 is released in the blood and transported to the kidneys, where a 25-
hydroxyvitamin D-1α-hydroxylase called CYP27B1 converts 25(OH)D3 to the active form 
1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), also called calcitriol (1,2,9). 1,25(OH)2D3 is 
transported in the blood to different tissues in the body and function like a steroid 
hormone that bind to cell membrane and nuclear vitamin D receptors (VDR) to regulate 
gene expression (1,9).  
 
Vitamin D metabolism is tightly regulated based on calcium and phosphorus levels (1,2). 
Low serum calcium levels activate the calcium receptors on the parathyroid glands. This 
cause an increased release of parathyroid hormone (PTH), which in turn stimulates the 
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kidneys to increase the activity of 25(OH)D-1α-hydroxylase, which result in increased 
serum levels of calcitriol (1). Low phosphorus levels also lead to an increased activity of 
25(OH)D-1α-hydroxylase to increase the circulating levels of calcitriol. Low levels of 
both calcium and phosphorus substantially increase the activity of 25(OH)D-1α-
hydroxylase and thereby lead to high levels of calcitriol as a protective mechanism to 
normalize calcium and phosphorus levels (1).  
 
The breakdown of calcitriol also occurs in the kidneys, and this catabolism is also tightly 
regulated based on calcium and phosphorus levels. 25(OH)D-24-hydroxylase (CYP24A1) 
is the catabolic enzyme responsible for the degradation of 1,25(OH)2D3 to calcitroic acid, 
which is then excreted in the bile (1,2). High levels of PTH and calcitriol increases the 
activity of the 25(OH)D-24-hydroxylase, while low serum phosphorus levels down-
regulate the activity of the 25(OH)D-24-hydroxylase and thereby the degradation of 
calcitriol to maintain sufficient serum levels (1,2).  
 
1.1.3 Vitamin D functions 
The vitamin D receptor 
The actions of vitamin D are mediated through the vitamin D receptor (VDR), a ligand-
activated transcription factor located in the target tissues (1,2,13). Binding of 
1,25(OH)2D3 to the VDR leads to the formation of two independent protein interaction 
surfaces on the VDR, one that allows binding of the heterodimer retinoid X-receptor 
(RXR), and one that is necessary for recruitment of large coregulatory complexes 
required for regulation of gene expression (1). The VDR recognizes a specific DNA 
sequence called vitamin D response element (VDRE), and the VDR-RXR complex binds to 
the VDRE. The regulation of gene expression is not mediated directly by the VDR, but 
indirectly through the recruitment of coregulatory complexes with the ability to make 
the desired changes of gene expression (1). These coregulatory complexes contain one 
VDR-interacting component, as well as many subunits with different enzymatic 
functions that acts by enhancing or suppressing the expression of the targeted genes (1). 
This way, through binding to the VDR and regulating gene expression, vitamin D has the 
ability to regulate the activity and different functions in a number of cells and tissues.  
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Effects of vitamin D 
The primary function of vitamin D is to maintain calcium and phosphorus homeostasis 
(1,2). Serum calcium levels should be maintained at a very constant level, at 2.1 to 2.6 
mmol/L, to attain and maintain a healthy bone mineral density (12). Vitamin D has three 
primary functions with the intent of increasing calcium levels if they fall below normal 
levels, which include stimulating the absorption of calcium and phosphorus in the 
intestine, mobilization of calcium and phosphorus from the bone tissue, and also 
stimulating reabsorption of calcium in the renal tube (2,12).  
 
The VDR has also been found in tissues besides the ones involved in calcium and 
phosphorus metabolism, including the islet cells of the pancreas, the parathyroid glands, 
B cells and T cells of the immune system, in the macrophages, in epithelial cells of the 
intima of blood vessels, in cells of the stomach, in keratinocytes of skin, in epithelial cells 
of the colon, and in cells of the placenta (1,2,12). Thus, vitamin D has several non-
skeletal functions (1,2,12). Among the observed functions of vitamin D, it has been found 
to affect the keratinocytes (1,13), maintaining parathyroid status (1,12), and have an 
impact on the immune system (1,12,14). However, it is still a work in progress to 
investigate the wide range of non-skeletal effects of vitamin D.  
 
1.1.4 Sources of vitamin D 
Dietary sources of vitamin D are quite limited and include fatty fish, cod liver oil, egg 
yolk, and foods fortified with vitamin D, such as dairy products. Vitamin D supplements 
are also an important source of vitamin D in some parts of the population (1,15).  
However, exposure of sunlight on the skin is considered to be the most important source 
of the vitamin (1,2). Vitamin D occurs in two different structural forms, named vitamin 
D2, or ergocalciferol, and vitamin D3, or cholecalciferol. Vitamin D2 is found in plant 
sources like mushrooms and yeast, while vitamin D3 is found in animal and fortified 





1.1.5 Recommended vitamin D levels 
25(OH)D is the circulating form measured to determine vitamin D status (1,9). The 
Nordic Nutrition Recommendations 2012 (16), the US Institute of Medicine (17), and the 
recommendations from Germany, Austria, and Switzerland (18) consider a serum level 
of above 50 nmol/L 25(OH)D (20 ng/mL) as sufficient, while a level of under 30 nmol/L 
(12 ng/mL) is regarded as deficient (19). However, the levels of serum 25(OH)D 
considered as adequate and the definition of vitamin D deficiency has been widely 
discussed. In parts of the literature, a serum level of above 30 ng/mL (75 nmol/L) 
25(OH)D is considered to be sufficient to optimize health, while levels under 20 ng/mL 
(50 nmol/L) is considered as a vitamin D deficiency (1,9,20). There have also been 
uncertainties regarding the daily intake of vitamin D needed to achieve the optimal 
serum levels of 25(OH)D, and the recommendations vary across different countries and 
health authorities. The US recommendation for vitamin D intake to achieve the 
recommended level of 50 nmol/L to support bone health is set to 15 µg for children and 
adults (17), while the dietary guidelines from Germany, Austria, and Switzerland have 
estimated adequate vitamin D intake to be 20 µg/d for children, adolescents, and adults 
(18). However, the Nordic recommendations to maintain sufficient serum levels is set to 
10 µg/d for children, adults, pregnant women, and lactating women, and 20 µg/d for 
adults over 75 years old (19).  
 
Highly increased serum levels of 25(OH)D are toxic and can lead to consequences like 
hypercalcaemia, hyperphosphatemia, nephrocalcinosis, and kidney failure (1,19). Serum 
25(OH)D concentrations above 375 nmol/L indicates vitamin D toxicity (21). This 
usually occurs with excessive oral intake, most often associated with supplementation 
above the recommended doses (1,21). The tolerable upper intake level (UL) is set to 100 
µg/d for adults and adolescents, 50 µg/d for children 1−10 years of age, and 25 µg/d for 
infants (19). Excessive sunlight exposure will not cause vitamin D intoxication due to 
photodegradation of previtamin D3 to inactive sterols in the skin, in addition to the 





1.1.6 Vitamin D deficiency 
Prevalence  
The prevalence of vitamin D deficiency varies across different parts of the world and 
between different population groups. Reviews aimed at providing an overview of the 
global vitamin D status have found that vitamin D deficiency is a global problem 
affecting all age groups, but the prevalence is particularly high in girls and women from 
the middle east (3,8).  
 
Data from “The Tromsø study” and “The North Trøndelag health study” show that a 
large proportion of the Norwegian adult population has suboptimal serum 25(OH)D 
levels (below 50 nmol/L), while a relatively small proportion have levels below 25 
nmol/L, considered as deficient (23). The vitamin D status varies across different groups 
in the Norwegian population, and it has been found that among the adult ethnic 
Norwegian population aged 45−75, the majority have sufficient vitamin D levels, while 
among the elderly at nursing homes and the non-western immigrants, it is estimated 
that more than 70% have insufficient serum 25(OH)D levels (24).  
 
Consequences of vitamin D deficiency 
Vitamin D deficiency has primarily been associated with detrimental effects on bone 
health. Lack of vitamin D affects the calcium homeostasis, causing decreased calcium 
absorption in the intestine and reabsorption of calcium in the kidneys, decreased levels 
of calcium in the blood, and thereby impaired bone mineralization (1,2,9). A 
consequence of severely deficient vitamin D and calcium levels in children is poor bone 
development and the condition rickets, characterized by bowed legs, knock knees, and 
growth retardation (1,9,11). In adults, vitamin D deficiency could cause impaired bone 
mineralization leading to the bone disease osteomalacia and increased risk of 
osteoporosis (1,2).  
 
The vitamin D receptor (VDR) is also found in muscle tissue, and vitamin D deficiency 
has been shown to impair muscle function and cause muscle weakness, which in turn 
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increases the risk of falling (11,25). A proposed explanation of the effect of vitamin D on 
muscle function and the risk of falling is that 1,25(OH)2D binds to a vitamin D receptor 
in muscle tissue stimulating de novo protein synthesis, muscle cell growth, and improved 
muscle function (1,25). Closely related to the effects on muscle function and risk of 
falling is the connection between vitamin D status and fracture risk. A dose-dependent 
associations between vitamin D status and the risk of fractures have been observed 
(1,25). A meta-analysis found that supplementing with 10 µg/d or below did not reduce 
the risk of fractures, while vitamin D supplementation at 12.5 to 17.5 µg/d and higher 
achieved serum 25(OH)D levels that seemed to reduce the risk of nonvertebral fractures 
by 20% and hip fractures by 18% (26).  
 
In addition to the detrimental effects on bone health and muscle function, vitamin D 
deficiency is associated with increased risk of several chronic diseases, including CVD, 
autoimmune diseases, infectious diseases, multiple sclerosis, type 1 diabetes, and 
different forms of cancer (1,2,11).  
 
Both excessive and insufficient vitamin D status have been suggested to be associated 
with an increased risk of CVD (1,2). In observational studies from the 1980s, it was 
observed a seasonal variation in cases of cardiovascular events in accordance with 
varying sunlight exposure, and it was hypothesized that vitamin D is associated with the 
risk of CVD (1). Insufficient vitamin D status is associated with several different risk 
factors of CVD, including hypertension, peripheral vascular disease, diabetes mellitus, 
and abnormal lipid profiles (2,27–32). Furthermore, several meta-analyses found that 
low levels of serum 25(OH)D were associated with an increased risk of CVD (33,34). 
Potential mechanisms explaining the protective effects of vitamin D against CVD include 
beneficial effects on cardiac function, blood pressure, insulin resistance, lipid 
metabolism, and inflammatory processes (1). Studies investigating the effects of vitamin 
D supplementation on the risk of CVD are, however, inconsistent, and it is yet premature 




The abilities of vitamin D to regulate gene expression in several different tissues have 
led to the hypothesis that vitamin D could have anti-cancer effects and that vitamin D 
status affects cancer risk (1). Activation of VDR by binding of calcitriol elicit a wide 
variety of responses, which could influence cellular growth, proliferation, apoptosis, and 
immune function, and thereby affecting the risk of cancer development (1,38). Vitamin D 
also seems to have angiogenesis inhibitory effects causing tumor growth retardation and 
tumor regression (1,38).  
 
Associations between serum 25(OH)D levels and different types of cancers, including 
colorectal cancer, breast cancer, and prostate cancer, have been suggested (1,11,16). A 
meta-analysis indicated that circulating 25(OH)D was inversely associated with cancer 
incidence and cancer mortality (39), and that serum 25(OH)D levels were inversely 
related to the risk of colorectal cancer, but no association was found for breast and 
prostate cancer (40). When looking at the effects of vitamin D supplementation on 
cancer incidence and mortality, the results are inconclusive (41,42). 
 
Immunomodulatory and anti-inflammatory effects of vitamin D have also been 
hypothesized, and it has been suggested that vitamin D may thereby affect the risk of 
developing autoimmune diseases (1,43). A meta-analysis looking at the effects of 
vitamin D on systemic inflammation and autoimmune disease concluded that the data 
was insufficient to indicate a relation between vitamin D and reduced risk of 
autoimmune disease (14). However, several meta-analyses investigating the 
relationship between rheumatoid arthritis and vitamin D status have found that patients 
with rheumatoid arthritis have lower serum 25(OH)D compared to healthy controls, and 
that there is a negative association between serum 25(OH)D and rheumatoid arthritis 
disease activity (44,45). Similar results have been observed when looking at associations 
between vitamin D status and type 1 diabetes, where subjects with type 1 diabetes had 
6.3 nmol/ lower serum 25(OH)D levels compared to the control group (46). 
 
Vitamin D deficiency has also been suggested to increase the risk of infectious diseases 
(47), and vitamin D has been proposed to have a protective effect on diseases like 
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respiratory tract infections and tuberculosis (1,48,49). Some meta-analyses found that 
vitamin D supplementation reduced the risk of acute respiratory tract infection (odds 
ratio (OR) 0.64 and odds ratio 0.88), where the protective effects were strongest in 
those with profound vitamin D deficiency at baseline (49,50), while another meta-
analysis observed a weaker protective effect of vitamin D supplementation on the risk of 
respiratory tract infections in previously healthy individuals (relative risk (RR) 0.94) 
(48). When looking at the associations between vitamin D and tuberculosis, some meta-
analyses found that vitamin D deficiency is associated with an increased risk of 
tuberculosis (51,52).  
 
Vitamin D also seems to influence brain function, and it has been found associations 
between insufficient vitamin D status and several neurological diseases, including 
schizophrenia, Parkinson´s disease, Alzheimer´s disease, and reduced cognitive function 
(53,54). Data from experimental trials indicate that vitamin D is a neuroactive steroid, 
and that vitamin D signaling is involved in brain development and function in adults 
(53,54). Meta-analyses found that lower 25(OH)D levels were associated with poorer 
cognitive function (55) and that individuals with Alzheimer’s disease had lower 
25(OH)D concentrations compared to healthy controls (55,56).  
 
In addition to the range of chronic diseases, several studies have also found an inverse 
relationship between 25(OH)D levels and all-cause mortality (57,58). However, the 
effect of vitamin D supplementation on all-cause mortality is unclear. Some meta-
analyses found that intake of vitamin D supplements were associated with decreased 
total mortality rates (59,60), while another analysis observed no association between 
vitamin D supplementation and all-cause mortality (61).   
 
1.1.7 Factors associated with vitamin D status 
Vitamin D status is affected by several different factors, both modifiable and non-
modifiable. Among the modifiable factors are sunlight-exposure, vitamin D content in 
the diet, bodyweight, smoking, and lifestyle factors such as physical activity (6,7,62–64). 
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The non-modifiable factors include gender, age, and skin-color (6,7,62,63,65). However, 
there is still uncertainty regarding determining factors of vitamin D status and potential 
risk factors of vitamin D deficiency. This thesis is based on a cohort of patients with 
stable angina pectoris (SAP). A previous study based on these data found that serum 
25(OH)D concentrations were inversely associated with cardiovascular mortality (66), 







Vitamin D has a wide variety of functions in the human body, and insufficient vitamin D 
levels may have major health consequences. Importantly, the prevalence of insufficient 
serum 25(OH)D levels is high, and potential determinants of vitamin D status are not 
fully elucidated. This thesis aimed to explore a wide variety of factors, both demographic 
characteristics, anthropometric measures, biochemical variables, and dietary data, to 
investigate which factors were associated with serum 25(OH)D levels, measured at 
baseline in a large cohort of patients with stable angina pectoris.  
 
Specific objectives  
• Assess cross-sectional associations between 25(OH)D serum levels and a variety 
of dietary, clinical, and biochemical variables by linear regression modeling.  
• Explore associations between serum 25(OH)D and dietary, clinical and 
biochemical variables at different levels of 25(OH)D by quantile regression 
analysis.  
• Assess the strengths of linear relationships between serum 25(OH)D levels and 










This was a cross-sectional study based on data obtained from the Western Norway 
Coronary Angiography Cohort (WECAC), investigating factors associated with serum 
25(OH)D levels at baseline in a large clinical cohort. WECAC included the participants 
from both Bergen Coronary Angiography Cohort (BECAC) and Western Norway B Vitamin 
Intervention Trial (WENBIT). BECAC was a prospective cohort study that followed 
patients who underwent elective coronary angiography at Haukeland University 
Hospital between January 2000 and April 2004 (67). The overall aim of BECAC was to 
study various prognostic markers of cardiovascular endpoints and cause-specific 
mortality in patients with suspected heart diseases (67). WENBIT (ClinicalTrials.gov 
Identifier: NCT00354081) was a randomized, controlled, double blind study 
investigating effects of homocysteine-lowering therapy on mortality and cardiac events 
in patients undergoing coronary angiography, hypothesizing that a daily supplement 
with B vitamins would reduce the risk of cardiovascular mortality and serious 
cardiovascular events among patients with coronary artery disease (68).  
 
The inclusion criteria for the cohort was age over 18 years, patients able to give 
informed consent, with and without significant coronary artery disease (CAD) who had 
undergone coronary angiography just before inclusion, and was prepared to undergo 
long-term follow-up (67,68). Patients with known alcohol abuse or serious mental 
illness, or with known active malignant disease were not eligible to participate in the 
study. The study was conducted according to the Declaration of Helsinki and approved 
by the Regional Committee for Medical and Health Research Ethics and the Norwegian 
Data Protection Authority, and written informed consent was obtained from all 
participants (68). 
 
In total 5210 men and women who underwent coronary angiography at Haukeland 
University Hospital or Stavanger University Hospital between April 1999 and April 2004 
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were included in BECAC and WENBIT (4241 patients were included in BECAC and an 
additional 969 patients were included in WENBIT). From this cohort, a total of 4166 
patients with suspected or verified stable angina pectoris (SAP) were eligible for 
inclusion. Of these patients, 4118 had available measures of 25(OH)D concentrations 
and were included in the analyses in the current thesis (Figure 1).  
 
 
Figure 1. Flow of subjects from BECAC and WENBIT with stable angina pectoris (SAP) and available measurements of 




3.2 Baseline characteristics 
Information about the participants was obtained by clinical examinations, 
anthropometric measurements, blood sampling, and questionnaires on lifestyle, medical 
history, and dietary habits. Self-administered questionnaires were used to obtain 
information on participants lifestyle, and medical history gave information about health 
status and was verified by comparing with hospital records. Smoking status was 
classified based on self-reported smoking habits and plasma cotinine levels. Current 
smoking was defined as a self-reported smoker, having stopped smoking less than 90 
days ago, or plasma cotinine levels above 85 nmol/L. Estimated glomerular filtration 
rates (eGFR) were calculated by using the formula suggested by the Chronic Kidney 
Disease Epidemiology Collaboration (69).  
 
3.2.1 Laboratory data 
Clinical examinations and blood sampling at baseline and during follow-up were 
conducted by trained study personnel. At Haukeland University Hospital, the blood 
samples were taken from non-fasting patients before the angiography, while at 
Stavanger University Hospital, fasting blood samples were taken in conjunction with the 
angiography. Routine blood analyses were performed at the hospital laboratories, while 
blood sample for biobanking were immediately prepared to serum and plasma and 
stored at −80°C until analyzed (68).  
 
Analyses of plasma 25(OH)D2 and 25(OH)D3 concentrations were performed by using 
liquid chromatography tandem mass spectrometry (LC-MS/MS) in the period between 
2011 and 2012 at Bevital AS, Bergen, Norway (66,68).  
 
3.2.2 Dietary data 
Information on dietary habits was obtained from a semiquantitative food frequency 
questionnaire (FFQ) the participants completed at enrollment (68,70). The FFQ was 
developed at the Department of Nutrition, University of Oslo, and included 169 food 
items that were grouped according to traditional Norwegian meal patterns. It was 
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designed to obtain information on usual food intake during the past year, including the 
frequency of consumption of different food groups and amounts given as household 
measures or units, such as slices or pieces. Questions on supplement use were also 
included in the FFQ. Based on the information from the FFQ, nutrient intake was 
calculated by using a database and software system developed at the Department of 
Nutrition, University of Oslo (Kostberegningssystem, version 3.2; University of Oslo, 
Norway).  
 
3.3 Statistical analysis 
Baseline characteristics of the study population are presented as arithmetic means and 
standard deviation (SD) for demographic characteristics, as number and percentages for 
categorical variables, and as geometric means and ranges (1SD ranges) for biochemical 
variables. The geometric SD ranges were calculated by dividing and multiplying the 
geometric means with the geometric SD factors to obtain the lower and upper limits, 
respectively. The descriptive statistics are categorized into quartiles of 25(OH)D levels. 
P-values for the linear trend across quartiles were derived from unadjusted linear 
regression models for the continuous variables, while unadjusted logistic regression 
models were used to derive p-values for trend across quartiles of 25(OH)D levels for the 
categorical variables. All statistical analyses were conducted with R, version 3.6.1 
(https://www.R-project.org) (71), and data transformation and exploration were done 
by using tidyverse packages (72).  
 
To assess the relationship between serum 25(OH)D levels and dietary, clinical, and 
biochemical variables linear regression analysis were used. Linear regression is a 
method to investigate associations between variables, and allows prediction of the 
values of the dependent variable based on the values of the independent variable (73). A 
simple linear regression model was used to assess the association between serum 
25(OH)D and the different parameters. In addition, multiple linear regression models 
were used to adjust for potential confounding factors, i.e., to isolate the relationship 
between serum 25(OH)D levels and the variable of interest from the effects of the 
confounding variables. Multiple regression allows inclusion of more than one 
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independent variable, and is used to reveal associations between multiple predictor 
variables and a single outcome variable (74). The first multiple regression model was 
adjusted for sex and age, and the second was adjusted for age, sex, BMI, smoking habits, 
and GFR. We adjusted for age, sex, BMI, smoking habits, and GFR as these covariates 
have been found to be associated with serum 25(OH)D levels (6,7,62,75), and also 
several of the variables of interest. Among observed relationships between potential 
confounders and the variables we investigated, are associations between BMI and 
biochemical variables, such as standard lipids and parameters glycemic control (76), the 
relationships of sex and age with amino acid profile (77) and lipid profile (78), and the 
associations between GFR and biochemical variables, such as vitamin status (79). The 
linear regression analyses were performed with the lm function, while logistic 
regression analyses were conducted with the glm function in the stats package, version 
3.6.2 (https://www.rdocumentation.org/packages/stats) (80). 
 
Quantile regression analysis was used to assess the relationship between 25(OH)D 
concentrations and the different parameters in selected quantiles of 25(OH)D. This type 
of regression analysis makes it possible to assess the relationship between the 
independent variables and serum 25(OH)D at different levels of 25(OH)D (81). This may 
disclose varying degrees of association between the independent variables and 25(OH)D 
in different categories of vitamin D status. Quantile regression was conducted both for 
the unadjusted model, the model adjusted for age and sex, and the model adjusted for 
age, sex, BMI, smoking habits, and GFR. The quantile regression analyses were 
performed with the lqm function in the quantreg package, version 5.51 (https://cran.r-
project.org/web/packages/quantreg/) (82).  
 
To estimate the strengths of linear relationships between serum 25(OH)D levels and the 
measured variables of interest on a standardized scale, Spearman`s rank correlation 
coefficients, rhos, with bootstrapped confidence intervals and p-values, were calculated. 
Spearman`s correlation measures the strength and direction of the monotonic 
relationship between two variables. A positive relationship, which implies that as the 
value of one of the variables increases so does the other variable, will give a positive 
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correlation coefficient, while a negative relationship, which implies that as the value of 
one variable increases the value of the other variable decreases, is shown as a negative 
correlation coefficient (83). The Spearman`s correlation coefficient can take values from 
−1 to +1, where a correlation coefficient of +1 indicates a perfect positive association, 
while a correlation coefficient of −1 indicates a perfect negative association, and a 
coefficient of 0 indicates that there is no association between the two variables (84). To 
control for the effects of potential confounding factors, partial correlation analyses were 
also conducted by adjusting for age and sex in one model, and for age, sex, BMI, smoking 
habits, and GFR in another model. The Spearman`s rank correlation coefficients were 
calculated with the cor.test function in the RVAideMemoire package and the partial 
correlations were estimated with the pcor.test function in the RVAideMemoire package, 
version 0.9-73 (https://cran.r-project.org/web/packages/RVAideMemoire) (85). 
 
3.3.1 Model validation 
Linearity, normality, and homoscedasticity are assumptions that should be met to justify 
the use of linear regression (73,86). In a linear regression model, it is assumed that the 
relationship between the dependent variable and the independent variables is linear. A 
linear regression model is also limited by the fact that it models the mean of the 
conditional probability distribution, and the results are more accurate if this distribution 
is normally distributed. The assumption of homoscedasticity includes that the variance 
of the residuals should be the same for all values of the independent variables. Through 
model validation, these assumptions can be checked to determine whether the chosen 
model is suitable for its purposes (87,88).  
 
To check for the assumptions of linearity, normality, and homoscedasticity, and examine 
the validity of the regression models in this thesis, graphical analyses of residuals were 
conducted. To assess the linearity, the residual values were plotted against predicted 
values of the independent variable in a scatter plot. The residuals were presented on the 
y-axis, while the predicted values were presented on the x-axis, and a horizontal line 
was drawn where the residuals equal zero. Residual plots showing no systematic 
pattern and a line approximately horizontal at zero, indicated linearity (86,89). In 
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addition, partial residual plots were used to assess linearity in the multiple regression 
models. In partial residual plots the dependent variable is adjusted for the linear effects 
of the independent variables except the one of interest. The partial residuals were 
plotted against predictive values for each of the independent variables in component-
plus-residual-plots. Plots with residuals randomly scattered close to the zero-line, 
indicated that the assumption of linearity was held (86). The assumption of 
homoscedasticity was evaluated by plotting square root standardized residuals against 
the predicted values of the independent variable. Residuals randomly spread along a 
horizontal line, indicated that the assumption of homoscedasticity was valid (86,89). To 
assess the assumption of normality of the residuals, a normal quantile-quantile (QQ) 
plot was used. In this plot, the quantiles of the observed residuals were plotted against 
the quantiles of the standard normal distribution, and where the points in the scatter 
plot followed along the 45 degree line, we assumed normality (86,89). The diagnostic 
plots and model validation in this thesis were conducted with the plot function in the 
ggfortify package, version 0.4.10 (https://cran.r-project.org/package=ggfortify) (90), 
and partial residual plots were made with the crPlots function in the car package, 
version 3.0-7 (91) (https://cran.r-project.org/package=car).  
 
Potential nonlinear associations between serum 25(OH)D and different variables was 
visualized by plotting the relationships using splined functions in the regression models, 
and the function geom_smooth in the package ggplot2, version 3.2.0 (https://cran.r-
project.org/web/packages/ggplot2).  
 
To visualize the results from the statistical analysis different plots and figures were 





4.1 Baseline characteristics 
Of the 4166 participants eligible for inclusion in this study, 48 were excluded due to 
missing data on serum 25(OH)D levels, and the remaining 4118 (2961 (72%) males and 
1157 (28%) females) were included in the analyses. The mean age (SD) in the study 
population was 61.8 (10.4) years. 
 
Geometric mean serum 25(OH)D level (1SD range) in the study group was 55.4 
(38.3−80.1) nmol/L, with a range from 3.37 nmol/L to 205 nmol/L. A total of 1423 
(35%) of the 4118 participants, had serum 25(OH)D concentrations below the 
recommended level of 50 nmol/L, while the remaining 2695 had serum 25(OH)D levels 
considered as sufficient. The baseline table is divided into quartiles of 25(OH)D levels, 
showing the linear trend of the different variables across the quartiles. Tables 1-4 
present baseline data on demographic characteristics, anthropometric measurements, 
levels of standard lipids, blood glucose, inflammatory markers, vitamin status, dietary 
data, amino acids, and amino acid metabolites, both in the total cohort and across 






















1Values are arithmetic means (SDs), geometric means (1SD range), and numbers (%) across quartiles of serum 25OH vitamin D levels. BMI, body mass index (kg/m2); 
eGFR, estimated glomerular filtration ratio. 2P-values are derived from unadjusted linear regression models for the continuous variables and logistic regression models 
for the categorical variables. 
 
  
Table 1. Demographic characteristics, anthropometric measurements, smoking habits, GFR and vitamin D intake of the study population at 
baseline across quartiles of 25OH vitamin D levels.1 
 
Variable 
 Quartiles of vitamin D levels  
Total cohort 
(n = 4118) 
Q1 
(n = 1030) 
Q2 
(n = 1029) 
Q3 
(n = 1030) 
Q4 
(n = 1029) 
P-value2 
25(OH)D (nmol/L) 55.4 (38.3, 80.1) 
 
34.0 (26.0, 44.4) 
 
51.3 (47.9, 55.0) 
 
64.1 (60.0, 68.4) 
 
84.3 (73.1, 97.1) 
 
 














































eGFR (mL/min/ 1,732) 85.5 (66.3, 110) 
 
88.4 (69.1, 113) 
 
86.9 (69.2, 109) 
 
84.2 (65.7, 108) 
 
















Vitamin D intake (µg/d) 10.8 (8.48) 7.95 (5.48) 9.88 (7.60) 11.8 (9.40) 12.9 (9.51) <0.001 
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Table 2. Standard lipids, blood glucose, and inflammatory markers in serum at baseline across quartiles of 25OH vitamin D levels.1 
 
Variable 
 Quartiles of vitamin D levels  
Total cohort 
(n = 4118) 
Q1 
(n = 1030) 
Q2 
(n = 1029) 
Q3 
(n = 1030) 
Q4 
(n = 1029) 
P-value2 
TG (mmol/L) 1.54 (0.92, 2.58) 
 
1.67 (0.96, 2.91) 1.54 (0.94, 2.52) 
 
1.49 (0.91, 2.46) 1.46 (0.89, 2.40) <0.001 
Total cholesterol 
(mmol/L) 
4.95 (3.97, 6.17) 
 
4.98 (3.95, 6.27) 4.94 (3.98, 6.13) 4.92 (3.96, 6.11) 4.96 (4.01, 6.13) 0.673 
LDL-C (mmol/L) 2.94 (2.11, 4.09) 2.95 (2.11, 4.12) 2.94 (2.13, 4.07) 
 
2.92 (2.10, 4.08) 
 
2.92 (2.10, 4.08) 
 
0.794 
HDL-C (mmol/L) 1.24 (0.78, 1.95) 
 
1.18 (0.90, 1.56) 1.23 (0.93, 1.62) 1.23 (0.57, 2.68) 
 
1.31 (1.00, 1.71) 
 
<0.001 
Non-HDL-C (mmol/L) 3.62 (2.69, 4.86) 3.71 (2.74, 5.02) 3.62 (2.71, 4.85) 
 
3.57 (2.67, 4.78) 
 
3.56 (2.65, 4.78) 
 
0.002 
ApoA-I (g/L) 1.29 (1.05, 1.59) 1.24 (1.00, 1.54) 1.28 (1.03, 1.58) 1.30 (1.07, 1.59) 1.35 (1.11, 1.63) 
 
<0.001 
ApoB (g/L) 0.87 (0.67, 1.14) 0.88 (0.67, 1.16) 0.87 (0.67, 1.14) 0.87 (0.67, 1.12) 0.87 (0.67, 1.13) 0.259 
Type 2 diabetes (n) 455 (11.0) 140 (13.6) 112 (10.9) 110 (10.7) 93 (9.04) <0.001 
HbA1c (%) 6.08 (4.91, 7.54) 
 
6.22 (4.98, 7.78) 
 
6.06 (4.90, 7.48) 
 
6.09 (4.95, 7.49) 
 
5.96 (4.81, 7.38) 
 
<0.001 
Serum glucose (mmol/L) 6.00 (3.69, 9.77) 
 
6.21 (4.54, 8.49) 
 
6.11 (4.62, 8.07) 
 
5.85 (2.55, 13.39) 
 
5.85 (4.39, 7.81) 
 
<0.001 
CRP (mg/L) 1.86 (0.59, 5.84) 
 
2.25 (0.59, 8.59) 
 
1.79 (0.63, 5.12) 
 
1.68 (0.57, 4.96) 
 
1.76 (0.61, 5.10) 
 
0.003 
Neopterin (nmol/L) 8.57 (5.85, 12.5) 
 
8.59 (5.75, 12.8) 
 
8.37 (5.72, 12.2) 
 
8.59 (6.11, 12.1) 
 
8.72 (5.85, 13.0) 0.006 
 
1Values are geometric means (1SD range), and numbers (%) across quartiles of serum 25OH vitamin D levels. TG, serum triglycerides; HDL-C, serum high density 
lipoprotein cholesterol; LDL-C, serum low density lipoprotein cholesterol; ApoA-I, Apolipoprotein A-I; ApoB, Apolipoprotein B; HBA1c, glycosylated haemoglobin; CRP, 




Table 3. Dietary data at baseline across quartiles of 25OH vitamin D levels.1 
 
Variable 
 Quartiles of vitamin D levels  
Total cohort 
(n = 4118) 
Q1 
(n = 1030) 
Q2 
(n = 1029) 
Q3 
(n = 1030) 
Q4 
(n = 1029) 
P-value2 
Riboflavin (µg/dL)  12.4 (5.90, 26.2) 
 
11.3 (5.62, 22.7) 
 
12.4 (5.97, 26.0) 
 
12.9 (6.20, 26.8) 
 
13.2 (5.91, 29.4) 
 
<0.001 
PL (nmol/L) 10.6 (5.43, 20.9) 
 
9.48 (5.12, 17.5) 
 
10.2 (5.42, 19.2) 
 
11.1 (5.74, 21.4) 
 
12.0 (5.64, 25.5) 
 
0.072 
PLP (nmol/L) 43.7 (24.0, 79.6) 
 
38.3 (20.8, 70.4) 
 
42.9 (24.3, 75.9) 
 
46.5 (26.0, 83.2) 
 
47.7 (25.8, 88.2) 
 
<0.001 
PA (nmol/L) 28.0 (14.3, 54.8) 
 
24.9 (13.5, 45.8) 
 
26.8 (14.5, 49.7) 
 
29.1 (14.9, 56.7) 
 
31.8 (15.0, 67.6) 
 
0.005 
Folate (nmol/L) 11.0 (5.99, 20.3) 
 
10.0 (5.55, 18.0) 
 
11.03 (6.06, 20.0) 
 
11.3 (6.21, 20.5) 
 
11.8 (6.22, 22.5) 
 
<0.001 
Cobalamin (pq/mL) 361 (228, 570) 
 
343 (214, 549) 
 
358 (231, 554) 
 
368 (238, 569) 
 
375 (232, 606) 
 
0.001 
MMA (nmol/L) 0.17 (0.12, 0.25) 0.17 (0.11, 0.26) 
 
0.17 (0.12, 0.24) 
 
0.17 (0.12, 0.24) 
 
0.17 (0.12, 0.25) 
 
0.736 
Vitamin A (µmol/L) 2.84 (2.25, 3.59) 2.71 (2.11, 3.48) 
 
2.79 (2.22, 3.50) 
 
2.88 (2.31, 3.60) 
 
2.99 (2.38, 3.74) 
 
<0.001 
Vitamin E (µmol/L) 30.2 (24.1, 38.0) 29.2 (22.8, 37.4) 
 
29.9 (24.0, 37.1) 
 
30.6 (24.6, 38.2) 
 
31.3 (25.2, 38.9) <0.001 
Low fat milk 
consumption (g/day) 
131 (188) 137 (203) 122 (179) 134 (187) 129 (183) 0.598 
Fish consumption (g/day) 110 (70.7) 96.1 (62.5) 112 (69.9) 112 (76.8) 119 (70.0) <0.001 
Egg consumption (g/day) 16.6 (11.9) 15.6 (11.9) 17.1 (11.8) 16.3 (11.7) 17.1 (11.9) 0.090 
 
1Values are arithmetic means (SDs) and geometric means (1SD range) across quartiles of serum 25OH vitamin D levels. PL, Pyridoxine levels; PLP, Pyridoxal 5-phosphate; PA, 
4-pyridoxic acid; MMA, methylmalonic acid. 2P-values are derived from unadjusted linear regression models. 
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Table 4. Serum levels of amino acids and amino acid metabolites at baseline across quartiles of 25OH vitamin D levels.1 
 
Variable 
 Quartiles of vitamin D levels  
Total cohort 
(n = 4118) 
Q1 
(n = 1030) 
Q2 
(n = 1029) 
Q3 
(n = 1030) 
Q4 
(n = 1029) 
P-value2 
Serine (µmol/L)  97.2 (26.1, 361) 
 
99.7 (41.0, 243) 
 
98.5 (28.5, 340) 
 
95.1 (21.0, 432) 
 
95.5 (21.0, 433) 
 
0.728 
Glycine (µmol/L)  211 (163, 272) 
 
206 (158, 268) 
 
209 (163, 269) 
 
211 (162, 274) 
 
216 (168, 278) 
 
<0.001 
DMG (µmol/L) 4.20 (2.99, 5.90) 
 
4.23 (2.92, 6.13) 
 
4.13 (2.98, 5.73) 
 
4.22 (3.05, 5.83) 
 
4.21 (3.00, 5.92) 
 
0.339 
Sarcosine (µmol/L)  1.50 (1.06, 2.12) 
 
1.43 (0.99, 2.06) 
 
1.50 (1.08, 2.10) 
 
1.51 (1.09, 2.10) 
 
1.56 (1.11, 2.20) 
 
<0.001 
Choline (µmol/L)  9.71 (7.48, 12.6) 
 
9.36 (7.01, 12.5) 
 
9.68 (7.58, 12.4) 
 
9.74 (7.57, 12.5) 
 
10.1 (7.83, 12.9) 
 
<0.001 
Betaine (µmol/L)  38.9 (28.3, 53.5) 
 
37.8 (27.0, 52.8) 
 
38.5 (28.1, 52.8) 
 
39.3 (28.8, 53.6) 
 
40.2 (29.5, 54.7) 
 
<0.001 
Methionine (µmol/L)  27.0 (20.8, 35.1) 
 
26.5 (20.3, 34.5) 
 
27.1 (20.9, 35.2) 
 
27.0 (21.1, 34.5) 27.4 (20.8, 36.0) 
 
0.023 
tHcy (µmol/L) 10.7 (7.75, 14.8) 
 
10.9 (7.65, 15.5) 
 
10.5 (7.70, 14.2) 
 
10.6 (7.87, 14.4) 
 
10.8 (7.79, 15.0) 
 
0.537 
tCys (µmol/L) 290 (254, 331) 
 
288 (252, 329) 
 
288 (253, 328) 
 
293 (257, 334) 
 




1Values are geometric means (1SD range) across quartiles of serum 25OH vitamin D levels. DMG, plasma dimetylglycine; tHcy, total homocysteine; tCys, total cysteine. 




4.2 Factors associated with vitamin D status 
The following sections present a summary of the results from the regression and 
Spearman`s correlation analyses investigating the associations between serum 25(OH)D 
levels and measured variables of interest.  
 
Vitamin D intake 
Data on estimated daily vitamin D intake was available for 2068 of the study 
participants. The mean vitamin D intake in the total population was estimated to 10.8 
(8.48) µg/d. 779 of the 2068 with available data on vitamin D intake had an estimated 
daily intake above the recommendation of 10 µg/d. Among the participants with serum 
25(OH)D levels above 50 nmol/L, the mean vitamin D intake was estimated to 11.9 (9.2) 
µg/d, while the mean daily intake among the subjects with serum levels below 50 
nmol/L was estimated to 8.3 (5.9) µg. Both the unadjusted and the adjusted regression 
and Spearman`s correlation analyses showed that vitamin D intake was positively 
associated with the serum 25(OH)D level (Tables 5 and 6). The fully adjusted 
regression model showed that each additional 1 µg higher daily vitamin D intake was 
associated with an increase in serum 25(OH)D of 0.47 nmol/L.  
 
Season 
Great variation was seen when analyzing the associations between month or season of 
the study visit and the measured serum 25(OH)D levels. The lowest vitamin D levels 
were measured in the subjects included in March, with a geometric mean (1SD range) 
serum 25(OH)D concentration of 49.5 (35.3−69.5) nmol/L, while the highest levels were 
observed in the blood samples taken in August, with a geometric mean (1SD range) of 
69.0 (53.4−89.0) nmol/L. This implies a difference of 19.5 nmol/L between the 
geometric means of the months with highest and lowest observed vitamin D levels.  
 
When categorizing date of study visit in quarters of the year, the results revealed a 
similar trend with lower serum 25(OH)D levels during the winter months compared to 
the summer months (Table 6). Blood samples in the period from January through March 
had the lowest serum 25(OH)D levels with a mean of 50.0 (34.8−71.8) nmol/L, while the 
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quarter with the highest levels of serum 25(OH)D was July through September with a 
mean of 66.5 (50.1−88.3) nmol/L. This relationship was also shown in the regression 
and correlation analyses, where the summer months were positively associated with 
serum 25(OH)D levels, while the winter months were negatively associated with vitamin 
D status in both the unadjusted and the adjusted models. The proportion of subjects 
included in the period from January to March with serum 25(OH)D levels below 50 
nmol/L, was estimated to 48%, while among subjects included in the period from July 
through August, the proportion with insufficient serum 25(OH)D levels was 14%. The 








Both the unadjusted linear regression and correlation analyses and the models adjusted 
for age and sex showed that both BMI and waist circumference were inversely related to 
serum 25(OH)D levels (Tables 5 and 6). When classified according to WHOs body mass 
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index classification (92), it was observed that subjects classified as “normal weight” 
(BMI 18.5−24.9) had a mean serum 25(OH)D concentration of 58.1 (40.5−83.3) nmol/L, 
the subjects in the “overweight” category (BMI 25.0−29.9) had a mean serum 25(OH)D 
level of 55.7 (38.5−80.5) nmol/L, while the subjects classified as “obese class 1” (BMI 
30.0−34.9), “obese class 2” (BMI 35.0−39.9), and “obese class 3” (BMI above 40) had 
mean serum 25(OH)D concentrations of 50.9 (35.8−72.4), 46.3 (31.0−69.0), and 43.6 
(29.5−64.4) nmol/L, respectively. 30% of the normal weight subjects had insufficient 
serum 25(OH)D levels, while 34 and 46% of the subjects categorized as overweight or 



















1 Values are regression coefficients (95% CI) and p-values. Regression coefficients represent the mean difference of 25(OH)D (nmol/L) per one 
unit increase of the predictor variable. BMI, body mass index; eGFR, estimated glomerular filtration rate. 2 Model 1: unadjusted; 3 Model 2: 




Table 5. Associations between serum 25(OH)D levels and demographic characteristics, anthropometric measurements, 
smoking habits, GFR, and vitamin D intake.1   
 






Variable Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
Age (years) 0.22 (0.16, 0.28) <0.001     
Sex (male = 1) 1.24 (−0.13, 2.61) 0.075     
BMI (kg/m2) −0.73 (−0.88, −0.57) <0.001 −0.67 (−0.82, −0.52)    
Current smoker (n) −2.92 (−4.33, −1.52) <0.001 −1.75 (−3.19, −0.31) 0.018   
eGFR (mL/min/ 1,732) −0.17 (−0.21, −0.14) <0.001 −0.16 (−0.20, −0.11) <0.001   
Waist circumference (cm) −0.19 (−0.25, −0.13) <0.001 −0.23 (−0.29, −0.17) <0.001 −0.04 (−0.15, 0.07) 0.473 




1Values are Spearman`s rhos (bootstrapped 95% CIs) and p-values. BMI, body mass index (kg/m2); eGFR, estimated glomerular filtration ratio. 2Model 1: 
unadjusted; 3Model 2: adjusted for sex and age; 4Model 3: adjusted for sex, age, BMI, smoking habits, and GFR. 5 Season 1, January−March; 6 Season 2, 
April−June; 7 Season 3, July−September; 8 Season 4, October−December. 
Table 6. Correlation between serum 25(OH)D levels and demographic characteristics, anthropometric measurements, smoking habits, GFR, 
and vitamin D intake.1 
 






Variable Spearman’s rho (95% CI) P-value Spearman’s rho (95% CI) P-value Spearman’s rho (95% CI) P-value 
Age (years) 0.10 (0.07, 0.14) <0.001     
Sex (1 = male) 0.03 (−0.00, 0.06) 0.041     
BMI (kg/m2) −0.14 (−0.17, −0.11) <0.001 −0.13 (−0.16, −0.10) <0.001   
Current smoker (n) −0.07 (−0.11, −0.04) <0.001 −0.05 (−0.08, −0.02) <0.001   
eGFR (mL/min/ 1,732) −0.15 (−0.18, −0.12) <0.001 −0.11 (−0.14, −0.08) <0.001   
Waist circumference (cm) −0.11 (−0.14, −0.08) <0.001 −0.13 (−0.16, −0.09) <0.001 −0.01 (−0.05, 0.02) 0.358 
Vitamin D intake (µg/d) 0.21 (0.17, 0.26) <0.001 0.21 (0.17, 0.26) <0.001 0.21 (0.17, 0.25) <0.001 
Season 0.18 (0.14, 0.22) <0.001 0.17 (0.13, 0.21) <0.001 0.17 (0.13, 0.21) <0.001 
Season 15 −0.22 (−0.26, −0.19) <0.001 −0.17 (−0.22, −0.15) <0.001 −0.16 (−0.22, −0.14) <0.001 
Season 26 −0.00 (−0.04, 0.04) 0.933 0.00 (−0.04, 0.03) 0.900 −0.01 (−0.04, 0.03) 0.291 
Season 37 0.25 (0.22, 0.29) <0.001 0.16 (0.15, 0.22) <0.001 0.15 (0.14, 0.22) <0.001 




The results showed that serum levels of 25(OH)D was positively associated with HDL-
cholesterol (HDL-C) and apolipoprotein (Apo) A-I, and inversely with triglycerides (TGs) 
in both the unadjusted and the adjusted linear regression models and Spearman`s 
correlation analyses (Tables 7 and 8, Figure 3). The fully adjusted linear regression 
model showed that each additional 0.1 mmol/L higher baseline HDL-C was associated 
with 0.6 nmol/L higher 25(OH)D. The geometric mean (1SD range) HDL-C level in 
subjects with sufficient 25(OH)D levels was 1.26 (0.75−2.13) mmol/L, while the 
geometric mean (1 SD range) HDL-C level in subjects with insufficient vitamin D status 
was 1.19 (0.90−1.58) mmol/L. 
 
 
Figure 3. Scatter plot and regression line from the unadjusted linear regression model. The left graph shows the 
relationship between HDL-C level and serum 25(OH)D level, while the right graph shows the association between TGs and 
serum 25(OH)D level. HDL-C, High density lipoprotein cholesterol; 25(OH)D, 25-hydroxyvitamin D, TG; triglycerides. 
 
Glucose metabolism 
Serum levels of 25(OH)D associated negatively with blood glucose, HbA1C, and being 
diagnosed with type 2 diabetes in both the unadjusted linear regression model and 
Spearman`s correlation analyses and the models adjusted for confounding variables 
(Tables 7 and 8). The number of participants diagnosed with type 2 diabetes in the 
study population was 455. The geometric mean (1SD range) serum 25(OH)D level in 
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these subjects were estimated to 51.9 (34.2−78.8) nmol/L, compared to 55.9 
(39.0−80.0) nmol/L in the participants without the diagnosis. 
 
Inflammation 
A negative relationship was observed between CRP and 25(OH)D levels in serum in both 
the unadjusted and adjusted regression models (Table 7). However, the fully adjusted 
quantile regression model showed that the negative association was stronger at lower 
levels of serum 25(OH)D, and the association was weaker at higher 25(OH)D levels. This 
relationship is presented in Figure 4. A similar trend was observed for the association 
between serum 25(OH)D and neopterin in the fully adjusted quantile regression model, 
where the negative association was stronger at lower levels of serum 25(OH)D, and the 
relationship disappeared at the upper quantiles of serum 25(OH)D (Supplemental 
Table 9). Thus, at lower levels of 25(OH)D, higher CRP and neopterin was associated 




Figure 4 Plot showing the association between serum 25(OH)D and CRP using a splined function in the 






















1 Values are regression coefficients (95% CI) and p-values. Regression coefficients represent the mean difference of 25(OH)D (nmol/L) per one unit 
increase of the predictor variable. TG, serum triglycerides; HDL-C, serum high density lipoprotein cholesterol; LDL-C, serum low density lipoprotein 
cholesterol; ApoA-I, Apolipoprotein A-I; ApoB, Apolipoprotein B; HBA1c, glycosylated haemoglobin; CRP, C-reactive protein. 2 Model 1: unadjusted; 3 
Model 2: adjusted for sex and age; 4 Model 3: adjusted for sex, age, BMI, smoking habits, and GFR.  
Table 7. Associations between 25(OH)D and standard lipids, blood glucose, and inflammatory markers in serum.1   
 Regression model 
Model 12 Model 23 Model 34 
Variable Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
TG (mmol/L) −1.69 (−2.20, −1.20) <0.001 −1.48 (−1.99, −0.98) <0.001 −1.11 (−1.62, −0.60) <0.001 
Total cholesterol 
(mmol/L) 
−0.11 (−0.64, 0.41) 0.673 0.06 (−0.46, 0.59) 0.814 0.15 (−0.37, 0.67) 0.582 
LDL-C (mmol/L) −0.08 (−0.68, 0.52) 0.794 0.07 (−0.53, 0.67) 0.822 0.16 (−0.43, 0.75) 0.602 
HDL-C (mmol/L) 6.68 (5.07, 8.29) <0.001 7.09 (5.40, 8.78) <0.001 6.01 (4.28, 7.74) <0.001 
Non-HDL-C (mmol/L) −0.82 (−1.34, −0.29) 0.002 −0.61 (−1.14, −0.09) 0.023 −0.39 (−0.91, 0.13) 0.142 
ApoA-I (g/L) 10.7 (8.45, 13.0) <0.001 12.1 (9.69, 14.5) <0.001 10.8 (8.41, 13.2) <0.001 
ApoB (g/L) −1.43 (−3.91, 1.05) 0.259 −0.64 (−3.11, 1.84) 0.615 0.13 (−2.33, 2.59) 0.917 
Type 2 diabetes (n) −3.32 (−5.28, −1.36) <0.001 −4.10 (-6.05, -2.14) <0.001 −2.29 (−4.26, −0.31) 0.023 
HbA1C (%) −0.97 (−1.42, −0.53) 
 
<0.001 −1.02 (−1.46, −0.57) <0.001 −0.75 (−1.19, −0.31) 0.001 
Serum glucose (mmol/L) −0.59 (−0.85, −0.34) <0.001 −0.67 (−0.92, −0.41) <0.001 −0.44 (−0.70, −0.19) 0.001 
CRP (mg/L) −0.13 (−0.22, −0.05) 0.003 −0.14 (−0.22, −0.05) 0.001 −0.12 (−0.20, −0.04) 0.005 




1Values are Spearman`s rhos (bootstrapped 95% CIs) and p-values. TG, serum triglycerides; HDL-C, serum high density lipoprotein cholesterol; LDL-C, serum low 
density lipoprotein cholesterol; ApoA-I, Apolipoprotein A-I; ApoB, Apolipoprotein B; HBA1c, glycosylated haemoglobin; CRP, C-reactive protein. 2 Model 1: 
unadjusted; 3 Model 2: adjusted for sex and age; 4 Model 3: adjusted for sex, age, BMI, smoking habits, and GFR.  
 
Table 8. Correlation between 25(OH)D and standard lipids, blood glucose and inflammatory markers in serum.1   
 






Variable Spearman’s rho (95% CI) P-value Spearman’s rho (95% CI) P-value Spearman’s rho (95% CI) P-value 
TG (mmol/L) −0.09 (−0.12, −0.06) <0.001 −0.08 (−0.11, −0.05) <0.001 −0.05 (−0.08, −0.02) <0.001 
Total cholesterol (mmol/L) −0.00 (−0.03, 0.03) 0.990 0.01 (−0.02, 0.04) 0.523 0.01 (−0.02, 0.05) 0.466 
LDL-C (mmol/L) −0.00 (−0.03, 0.03) 0.889 0.01 (−0.02, 0.04) 0.735 0.01 (−0.02, 0.04) 0.712 
HDL-C (mmol/L) 0.14 (0.11, 0.17) <0.001 0.15 (0.12, 0.18) <0.001 0.13 (0.10, 0.16) <0.001 
Non-HDL-C (mmol/L) −0.04 (−0.08, −0.01) 0.006 −0.03 (−0.06, −0.00) 0.030 −0.02 (−0.05, 0.01) 0.110 
ApoA-I (g/L) 0.15 (0.12, 0.18) <0.001 0.17 (0.14, 0.20) <0.001 0.15 (0.12, 0.19) <0.001 
ApoB (g/L) −0.02 (−0.05, 0.01) 0.217 −0.01 (−0.04, 0.02) 0.477 −0.00 (−0.03, 0.03) 0.703 
Type 2 diabetes (n) −0.05 (−0.08, −0.02) 0.001 −0.02 (−0.05, −0.00) 0.123 −0.02 (−0.04, 0.01) 0.143 
HbA1C (%) −0.08 (−0.11, −0.05) <0.001 −0.08 (−0.11, −0.05) <0.001 −0.06 (−0.09, −0.03) <0.001 
Serum glucose (mmol/L) −0.08 (−0.11, −0.05) <0.001 −0.09 (−0.13, −0.06) <0.001 −0.07 (−0.10, −0.04) <0.001 
CRP (mg/L) −0.09 (−0.12, −0.06) <0.001 −0.09 (−0.12, −0.06) <0.001 −0.06 (−0.09, −0.03) <0.001 




Serum 25(OH)D levels associated positively with sarcosine and choline levels in both the 
unadjusted and adjusted regression models and Spearman`s correlation analyses. An 
inverse association was found between serum 25(OH)D level and total homocysteine 
and DMG in the fully adjusted regression model (Tables 9 and 11). The fully adjusted 
quantile regression analysis showed that the negative association between total 
homocysteine and vitamin D status was stronger at lower levels of serum 25(OH)D, and 
that the relationship disappeared at the upper quantiles of serum 25(OH)D 
(Supplemental Table 11). The association between serum 25(OH)D and total 
homocysteine is presented in Figure 5. 
 
 
Figure 5 Plot showing the association between serum 25(OH)D and tHcy using a splined function in the 
unadjusted regression model. 25(OH)D, 25-hydroxyvitamin D; tHcy, total homocysteine. 
 
Vitamin status and dietary variables 
Serum 25(OH)D levels was positively related to fish and egg consumption. Positive 
associations were also found for serum levels of vitamin A, vitamin E, riboflavin, 
pyridoxal phosphate (PLP), 4-pyridoxic acid (PA), folate, and cobalamin in both the 
unadjusted and the adjusted linear regression models and Spearman`s correlation 
analyses (Tables 10 and 12).  
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Figure 6 presents Spearman`s correlation coefficients and bootstrapped confidence 
intervals for the key observations of associations between serum 25(OH)D and the 
different variables, showing the direction and strength of the relationships on a 
standardized scale. Results from the quantile regression analyses investigating the 
associations between different quantiles of 25(OH)D and the independent variables are 
presented in the Supplemental Tables 1-4 for the unadjusted model, Supplemental 
Tables 5-8 for the model adjusted for age and sex, and Supplemental Table 9-12 for 




Table 9. Associations between serum 25(OH)D and amino acid levels.1  






Variable Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
Serine (µmol/L)  −0.01 (−0.03, 0.02) 0.728 0.00 (−0.03, 0.03) 0.867 −0.01 (−0.04, 0.02) 0.492 
Glycine (µmol/L)  0.02 (0.01, 0.03) <0.001 0.02 (0.01, 0.03) <0.001 0.01 (−0.01, 0.02) 0.301 
DMG (µmol/L) −0.07 (−0.21, 0.07) 0.339 −0.11 (−0.25, 0.02) 0.109 −0.17 (−0.31, −0.03) 0.016 
Sarcosine (µmol/L)  2.62 (1.62, 3.61) <0.001 2.50 (1.51, 3.49) <0.001 1.79 (0.80, 2.78) <0.001 
Choline (µmol/L)  0.81 (0.58, 1.04) <0.001 0.62 (0.38, 0.86) <0.001 0.46 (0.20, 0.71) <0.001 
Betaine (µmol/L)  0.09 (0.04, 0.13) <0.001 0.06 (0.02, 0.11) 0.006 0.03 (−0.02, 0.08) 0.199 
Methionine (µmol/L)  0.09 (0.01, 0.17) 0.023 0.09 (0.02, 0.17) 0.020 0.07 (−0.01, 0.15) 0.088 
tHcy (µmol/L) 0.04 (−0.09, 0.16) 0.537 −0.07 (−0.19, 0.06) 0.302 −0.26 (−0.39, −0.12) <0.001 
tCys (µmol/L) 0.03 (0.02, 0.05) <0.001 0.01 (−0.01, 0.03) 0.255 0.00 (−0.02, 0.02) 0.967 
 
1 Values are regression coefficients (95% CIs) and p-values. Regression coefficients represent the mean difference of 25(OH)D (nmol/L) per one unit 
increase of the predictor variable. DMG, plasma dimetylglycine; tHcy, total homocysteine; tCys, total cysteine. 2 Model 1: unadjusted; 3 Model 2: adjusted 




Table 10. Associations between serum 25(OH)D levels, vitamin status, and dietary variables.1 
 Regression model 
Model 12 Model 23 Model 34 
Variable Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
Riboflavin (µg/dL)  0.05 (0.03, 0.07) <0.001 0.04 (0.02, 0.06) <0.001 0.04 (0.02, 0.06) <0.001 
PL (nmol/L) 0.01 (0.00, 0.01) 0.072 0.01 (0.00, 0.01) 0.062 0.01 (0.00, 0.01) 0.075 
PLP (nmol/L) 0.03 (0.02, 0.04) <0.001 0.03 (0.02, 0.04) <0.001 0.03 (0.01, 0.04) <0.001 
PA (nmol/L) 0.01 (0.00, 0.01) 0.005 0.01 (0.00, 0.01) 0.006 0.01 (0.00, 0.01) 0.030 
Folate (nmol/L) 0.11 (0.06, 0.12) <0.001 0.10 (0.05, 0.15) <0.001 0.09 (0.05, 0.14) <0.001 
Cobalamin (pq/mL) 0.00 (0.00, 0.00) 0.001 0.00 (0.00, 0.01) 0.001 0.00 (0.00, 0.01) 0.004 
MMA (nmol/L) −0.50 (−3.38, 2.39) 0.736 −1.73 (−4.61, 1.15) 0.238 −2.73 (−5.58, 0.12) 0.061 
Vitamin A (µmol/L) 4.51 (3.65, 5.37) <0.001 4.59 (3.74, 5.45) <0.001 4.25 (3.31, 5.18) <0.001 
Vitamin E (µmol/L) 0.26 (0.18, 0.34) <0.001 0.27 (0.19, 0.35) <0.001 0.27 (0.19, 0.34) <0.001 
Low fat milk consumption 
(g/day) 
0.00 (−0.00, 0.01) 0.598 0.00 (−0.00, 0.01) 0.356 0.00 (−0.00, 0.01) 0.384 
Fish consumption (g/day) 0.03 (0.02, 0.04) <0.001 0.03 (0.02, 0.04) <0.001 0.03 (0.02, 0.04) <0.001 
Egg consumption (g/day) 0.06 (−0.01, 0.13) 0.090 0.07 (−0.00, 0.14) 0.056 0.11 (0.04, 0.18) 0.003 
 
1 Values are regression coefficients (95% CIs) and p-values. Regression coefficients represent the mean difference of 25(OH)D (nmol/L) per one unit 
increase of the predictor variable. PL, Pyridoxine levels; PLP, Pyridoxal 5-phosphate; PA, 4-pyridoxic acid; MMA, methylmalonic acid. 2 Model 1: 





















1 Values are spearman`s rhos (bootstrapped 95% CIs) and p-values. DMG, plasma dimetylglycine; tHcy, total homocysteine; tCys, total cysteine. 2 Model 1: 
unadjusted; 3 Model 2: adjusted for sex and age; 4 Model 3: adjusted for sex, age, BMI, smoking habits, and GFR.  
  
Table 11. Correlations between serum 25(OH)D and amino acid levels.1 
 






Variable Spearman’s rho (95% CI) P-value Spearman’s rho (95% CI) P-value Spearman’s rho (95% CI) P-value 
Serine (µmol/L)  0.00 (−0.03, 0.03) 0.888 0.01 (−0.02, 0.04) 0.607 −0.00 (−0.03, 0.03) 0.022 
Glycine (µmol/L)  0.07 (0.04, 0.10) <0.001 0.08 (0.05, 0.11) <0.001 0.02 (−0.01, 0.05) 0.314 
DMG (µmol/L) 0.01 (−0.03, 0.04) 0.662 −0.02 (−0.05, 0.01) 0.202 −0.04 (−0.07, −0.01) 0.005 
Sarcosine (µmol/L)  0.10 (0.07, 0.13) <0.001 0.10 (0.07, 0.13) <0.001 0.07 (0.04, 0.11) <0.001 
Choline (µmol/L)  0.09 (0.06, 0.12) <0.001 0.07 (0.03, 0.10) <0.001 0.05 (0.02, 0.08) 0.003 
Betaine (µmol/L)  0.09 (0.06, 0.12) <0.001 0.07 (0.04, 0.10) <0.001 0.04 (0.01, 0.07) 0.012 
Methionine (µmol/L)  0.04 (0.01, 0.07) 0.020 0.04 (0.01, 0.07) 0.026 0.02 (−0.01, 0.06) 0.193 
tHcy (µmol/L) 0.01 (−0.02, 0.04) 0.468 −0.03 (−0.06, 0.00) 0.058 −0.08 (−0.11, −0.05) <0.001 
tCys (µmol/L) 0.06 (0.02, 0.09) <0.001 0.01 (−0.02, 0.05) 0.395 −0.00 (−0.03, 0.03) 0.737 
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1Values are spearman`s rhos (bootstrapped 95% CIs) and p-values. Regression coefficients represent the mean difference of 25(OH)D (nmol/L) per one unit 
increase of the predictor variable. PL, Pyridoxine levels; PLP, Pyridoxal 5-phosphate; PA, 4-pyridoxic acid; MMA, methylmalonic acid. 2Model 1: unadjusted; 
3Model 2: adjusted for sex and age; 4Model 3: adjusted for sex, age, BMI, smoking habits, and GFR.  
Table 12. Correlations between serum 25(OH) D levels, vitamin status, and dietary variables.1 
 Correlation coefficients for unadjusted and adjusted models 
Model 12 Model 23 Model 34 
Variable Spearman’s rho (95% CI) P-value Spearman’s rho (95% CI) P-value Spearman’s rho (95% CI) P-value 
Riboflavin (µg/dL)  0.06 (0.04, 0.09) <0.001 0.05 (0.02, 0.08) 0.003 0.04 (0.01, 0.07) 0.022 
PL (nmol/L) 0.17 (0.14, 0.20) <0.001 0.16 (0.10, 0.18) <0.001 0.11 (0.06, 0.14) <0.001 
PLP (nmol/L) 0.15 (0.12, 0.18) <0.001 0.16 (0.13, 0.19) <0.001 0.14 (0.11, 0.17) <0.001 
PA (nmol/L) 0.17 (0.14, 0.20) <0.001 0.15 (0.10, 0.17) <0.001 0.07 (0.04, 0.11) <0.001 
Folate (nmol/L) 0.11 (0.08, 0.14) <0.001 0.11 (0.08, 0.14) <0.001 0.11 (0.08, 0.14) <0.001 
Cobalamin (pq/mL) 0.07 (0.04, 0.10) <0.001 0.08 (0.05, 0.12) <0.001 0.06 (0.03, 0.10) <0.001 
MMA (nmol/L) 0.05 (0.02, 0.08) 0.003 0.01 (−0.02, 0.04) 0.669 −0.03 (−0.06, −0.00) 0.018 
Vitamin A (µmol/L) 0.16 (0.13, 0.19) <0.001 0.16 (0.13, 0.19) <0.001 0.14 (0.11, 0.17) <0.001 
Vitamin E (µmol/L) 0.13 (0.10, 0.16) <0.001 0.14 (0.10, 0.17) <0.001 0.14 (0.10, 0.17) <0.001 
Low fat milk 
consumption (g/day) 
0.01 (−0.03, 0.05) 0.637 0.01 (−0.03, 0.05) 0.605 0.02 (−0.03, 0.06) 0.681 
Fish consumption (g/day) 0.12 (0.08, 0.16) <0.001 0.12 (0.08, 0.16) <0.001 0.13 (0.09, 0.17) <0.001 




Figure 6. Forest plot presenting Spearman`s rho and bootstrapped 95% CI for key findings of associations between serum 25(OH)D and variables of interest. Model 1: unadjusted; 
Model 2: adjusted for sex and age; Model 3: adjusted for sex, age, BMI, smoking habits, and GFR. BMI, body mass index (kg/m2); eGFR, estimated glomerular filtration ratio; Season 1, 
January-March; Season 3, July-September; TG, serum triglycerides; HDL-C, serum high density lipoprotein cholesterol; ApoA-I, Apolipoprotein A-I; HBA1c, glycosylated haemoglobin; 




5.1 Main results 
In this study, we explored a wide variety of variables to assess which were associated 
with serum 25(OH)D levels among 4118 patients with stable angina pectoris included in 
a large cohort. The results showed a seasonal variation of serum 25(OH)D 
concentration, with the highest concentrations measured in the blood samples taken in 
August and the lowest concentrations in the subjects included in March. Further, we 
found that serum levels of 25(OH)D were positively associated with dietary vitamin D, 
fish intake, and egg consumption, and with serum levels of HDL-C, riboflavin, PLP, PA, 
folate, cobalamin, vitamin A, vitamin E, choline, and sarcosine. Factors that showed an 
inverse relationship with serum 25(OH)D concentrations were BMI, and serum levels of 
TGs, blood glucose, HbA1C, and total homocysteine, DMG, and CRP at lower 25(OH)D 
serum levels.  
 
5.2 Discussion of methods 
5.2.1 Study design 
This was a cross-sectional study, a type of observational study design where the 
variables of interest are measured at the same time point (93). Cross-sectional studies 
can be used to investigate associations between risk factors and outcomes or 
relationships between different variables, as was the case in the present thesis (94). This 
study design gives the opportunity to investigate many variables at the same time that 
can be more rigorously assessed in future studies (94)(95).  
 
Cross-sectional studies are, however, limited by the fact that the outcome and the 
exposure are measured at the same time, and it is not possible to determine whether the 
exposure preceded the outcome, decide the direction of an association, and derive 
causal relationships (93)(94)(95). This principle of temporality is important to take into 





A strength in the present thesis is the relatively large study sample, with 4118 subjects 
included. The size of the study sample is important for the confidence in the estimates, 
because a larger sample size will be less affected by variability in a heterogeneous 
population. We have more available information, and so the uncertainty reduces (96–
98). On the other hand, very large sample sizes tend to show even small differences or 
associations as statistically significant results, and it is important to be aware of this 
when evaluating the results and distinguish between what is statistically and what is 
clinically significant associations (97).  
 
Study population 
A study sample is a finite part of participants included from the target population, while 
the target population is the entire set of subjects the researchers want to obtain 
information on (99). The results from analyses of the study population may be 
generalized to the target population to a certain degree, referred to as external validity. 
The source population in this study was patients in Western-Norway referred to 
coronary angiography for suspected coronary artery disease, and the target population 
was all patients with stable angina pectoris. The cohort in this thesis was characterized 
by a large proportion of older men, and was found to be quite similar to other 
populations who had verified coronary artery disease in other European hospitals (68). 
Hence, the results should be generalizable to other populations with stable angina 
pectoris. However, the results may not be generalized to the general population because 
the subjects with stable angina pectoris included may have several characteristics 
associated with CVD differentiating them from the general population. Further 
longitudinal studies of the general population are needed to draw conclusion regarding 
variables associated with vitamin D status in the general population.  
 
Data collection 
The data collection methods are prone to random and systematic errors, that could 
affect the precision and validity of the study (100). The sampling method is a potential 
source of both systematic and random errors, due to the fact that the sample is a 
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selection from the target population and large parts of the target population are for 
different reasons not included in the study (100,101). Selection bias occurs when a 
population is selected by some factors that create association between two variables 
when they are not associated in the target population (102). Collider stratification bias, a 
type of selection bias, occurs when we condition on a common effect of otherwise 
unrelated variables, and could lead to a spurious association between the variables 
(103). In the case of this thesis, if vitamin D status affects the risk of SAP, and thereby 
the chance of inclusion in the cohort, it could lead to spurious association between 
vitamin D status and other variables affecting the risk of SAP and chance of inclusion, 
due to selection bias. This kind of selection bias may introduce associations in the 
included cohort that do not exist in the general population.  
 
Random errors due to the study sample can be minimized by increasing the sample size 
(101). In WECAC, all available patients who underwent coronary angiography and 
fulfilled the inclusion criteria were recruited to the study, which lead to inclusion of a 
large study sample over a broad time period, and thereby reduced risk of random errors 
due to the sampling method. Non-response bias, that occur when subject who refuse to 
participate in the study are significantly different from the included subjects, may also 
bias the results (101). The observations in this study are probably not much affected by 
non-response bias, because of the design of the study with just one case of data 
collection, conducted in conjunction with elective coronary angiography, and the fact 
that participation did not require much effort from the participants. 
 
The measurements of key variables are also potential sources of random errors and may 
affect the precision of the study. The data on serum 25(OH)D concentrations included in 
our study were measured by LC-MS/MS at Bevital AS, a laboratory certified by the 
Vitamin D External Quality Assessment Scheme, with a between-day coefficient of 
variation (CV) of 7−8% (104), indicating a small degree of random errors in the included 




A potential source of systematic error in this study is the fact that blood sampling was 
conducted differently at Haukeland University Hospital and Stavanger University 
Hospital. At Haukeland University Hospital, blood sampling was done non-fasting prior 
to coronary angiography, while at Stavanger University Hospital, blood samples were 
taken after angiography and at least 8 hours of fasting. The non-standardized blood 
sampling could be a potential source of systematic error and reduce the validity in our 
study. This could have been handled by adjusting for site of study visit or non-fasting 
state of blood sampling, which could have reduced the risk of systematic error in the 
results.  
 
Parts of the data collection were done by self-administrated questionnaires to obtain 
information on diet, dietary supplements, smoking habits, medical conditions, and use of 
drugs. Questionnaires based on self-report may be subject to self-reporting bias, and are 
a potential source of systematic and random error in the data collection (105). Self-
reported data are prone to social desirability bias, where the reported data may be 
affected by underestimation or overestimation due to social desirability or approval. 
Another usual challenge with self-reported data is the ability to recall information. This 
type of bias is referred to as recall bias, and could potentially cause an underestimation 
or overestimation of the true associations (105). When conducting the data collection 
for WECAC, several measures were used to minimize the potential biases. Firstly, 
reported medical history was controlled against hospital records by trained personnel, 
and reported smoking status was complemented with measurement of cotinine 
concentration to provide an objective measurement. In addition, measurement of weight 
and anthropometry were conducted by trained personnel to minimize bias.  
 
Dietary data collection is prone to both social desirability bias and recall bias, and could 
be affected by overreporting of socially desirable behaviors and difficulties with 
recalling dietary habits. A semiquantitative food frequency questionnaire was designed 
in a way to obtain best possible information on usual food intake during the past year 
and minimize bias. However, the dietary data may still be a source of uncertainty in the 
data collection.  
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5.2.2 Statistical analysis 
In this cross-sectional study, we chose to conduct linear regression and Spearman`s 
correlation analyses to investigate associations and estimate effect sizes. Linear 
regression is used to measure the relationship between a dependent variable (outcome) 
and one or more independent variables (predictors). The Spearman`s correlation 
coefficient describes the strength and direction of the monotonic relationship between 
two variables, and linear regression also allows us to estimate how much the dependent 
variable either increases or decreases as the independent variables are changed 
(73,106).  
 
Importantly, linear regression is limited to linear and curvilinear relationships, and 
nonlinear associations may be missed (107). Linear regression is also limited by the fact 
that it investigates the relationship between the mean of the dependent variable and the 
independent variables, and in some cases, it is more valuable to look at the different 
levels of the dependent variable. We therefore also included quantile regression analysis 
to investigate the associations between serum 25(OH)D and the variables of interest at 
different serum levels of 25(OH)D.  
 
Quantile regression allows us to estimate the effect of an independent variable on a 
specified quantile of the dependent variable (81,108). Unlike linear regression, quantile 
regression makes no assumption about the distribution of the residuals, and can be used 
when the conditions of linear regression are not met (108,109). If the data are 
multimodal or highly skewed, quantile regression will be able to capture this 
relationship. Quantile regression is also more robust against outliers compared to the 
ordinary linear regression (108). Categorization of continuous variables and using them 
in analysis is also associated with some limitations. Such categorization lead to an 
assumption that the effect or association is homogeneous within each category (110). 
This assumption may reduce the power of the statistical test and the ability to detect 
associations. Categorization also makes it more difficult to compare results across 
different studies, because the categories used in the analyses depend on the study 
population and may differ between the compared studies (110). However, as an addition 
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to linear regression models, quantile regression may contribute to a more complete 
view of the associations of interest, especially in cases of nonlinear associations. The 
quantile regression analyses allowed us to assess the associations between serum 
25(OH)D and the independent variables at quartiles of serum 25(OH)D levels and 
explore potential nonlinear relationships.  
 
Another challenge in observational studies is the effect of confounding variables. A 
confounding variable is causally associated with both the dependent variable and the 
independent variable, and is not on the causal pathway between the exposure and 
outcome (111). Confounding variables lead to results that don`t reflect the actual 
relationship between the variables we want to study (112). To account for factors 
known to be associated with vitamin D status and several of the variables we wanted to 
investigate, we conducted multiple linear regression analyses in addition to the simple 
linear regression analyses. This way we adjust for the effect of known confounding 
variables to isolate the relationship of interest.  
 
P-value can be defined as “the probability that the chosen test statistic would have been 
at least as large as its observed value if every model assumption were correct, including 
the test hypothesis” (113). If the p-value is lower than the alpha level chosen, often 0.05, 
the association is stated to be statistically significant (113,114). However, statistical 
significance, or a small p-value, is not equivalent to scientific or clinical significance, and 
larger p-values do not imply a lack of importance (115). As mentioned, with a large 
sample, like in the current study, an inferential test may show statistically significant 
results even at very weak associations, while the effect sizes are not affected by the 
sample size (116,117). Although the significance level does not say anything about the 
size, direction, or clinical relevance of an association, the p-value is influenced by the 
variability in responses and may say something about the consistency in our findings 
(113). Notably, the interpretation of effect sizes estimated by linear regression and 
correlation analyses should be done with caution, and the clinical significance of an 
effect size also depends on theoretical background and comparison with previous work 
on the topic (116,118).  
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5.3 Discussion of results 
5.3.1 Sunlight exposure and season 
The results from this study showed a great variation of serum 25(OH)D in different 
months and quarters of the year. In line with several previous studies (6,117,118), we 
observed that serum 25(OH)D levels were higher during the quarter from July through 
September compared to the winter season. The seasonal variation observed in this and 
several previous studies is mainly explained by the fact that the sunlight exposure is 
insufficient for adequate vitamin D synthesis in the skin to maintain the vitamin D status 
throughout the winter months at the latitude of the Nordic countries (121). The UV 
radiation intensity is highest during the summer months and decreases during the 
winter. Besides, there is a greater degree of outdoor activities during the summer 
compared to the winter season, causing a considerable difference in serum 25(OH)D 
levels between summer and winter months (6,119).  
 
Sunlight exposure is reckoned as the major source of vitamin D for most people 
worldwide (1,120,121). A sufficient amount of sunlight exposure to stimulate the 
production of vitamin D3 in the skin can be enough to produce adequate levels of serum 
25(OH)D (1,19). It is estimated that during June and July in the Nordic countries 
exposure of sunlight to 25% of the body surface for about 6-8 minutes 2 to 3 times a 
week provides vitamin D equivalent to the recommended daily intake of 10 µg (19). The 
amount of vitamin D3 produced in the skin from sunlight exposure is also affected by 
exposed skin surface, use of sunscreen, and skin pigmentation, where skin type 4 (black 
skin) requires a higher degree of sunlight exposure compared to skin type 1 (white skin) 
to attain the same amount of vitamin D3 production (19,65). It has also been found that 
the production of vitamin D3 in the skin as a response to sunlight exposure is decreasing 
with age (65).  
 
Based on the observed seasonal variation of 25(OH)D concentrations, it has been 
discussed if single 25(OH)D measurements should be adjusted for seasonal variation to 
better assess vitamin D status (122–124). Seasonal variation in 25(OH)D concentrations 
implies that a person could have adequate 25(OH)D levels during the summer and 
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autumn months, but due to the reduced sunlight exposure, insufficient 25(OH)D levels in 
the winter and spring (123). It has been suggested that serum 25(OH)D concentration 
regarded as sufficient should vary according to season of blood sampling. In a study of 
healthy, postmenopausal women, and middle-aged and elderly men, the predicted sine 
curves indicated that serum 25(OH)D concentrations of 70-90 nmol/L in men and 60-70 
nmol/L in women during summer and fall were required to ensure 25(OH)D 
concentrations above 50 nmol/L throughout the year (123). Similarly, a study of the 
subjects in WECAC, using a cosinor model, estimated that a concentration of 65.8 
nmol/L would be required in August to remain vitamin D sufficient in February (122). 
These findings indicate that taking seasonal variation into account may increase the 
accuracy of the assessment of vitamin D status and improve the identification of patients 
at risk of developing insufficient vitamin D levels throughout the year.  
 
The results from this and previous studies indicate that sunlight exposure and seasonal 
variation are important determining factors of vitamin D status. However, vitamin D 
status is not explained in its entirety as a result of seasonal variation, and other 
variables also influence serum levels of 25(OH)D.  
 
5.3.2 Diet 
The positive association between serum 25(OH)D and daily vitamin D intake observed 
in this thesis, is in line with the results from several previous studies showing that 
estimated vitamin D intake is positively associated with serum 25(OH)D, and is one of 
the major determinants of vitamin D status (125–127).  
 
Some of the previous studies investigating determinants of vitamin D status found that 
estimated vitamin D intake did not affect the risk of insufficient or deficient vitamin D 
status (6,62). In these studies, it was observed that a higher estimated vitamin D intake 
did not decrease the risk of insufficient or deficient serum 25(OH)D concentrations, and 
the major determinants of vitamin D status was, however, season, latitude, age, obesity, 
and physical activity. In a study of a population of Danish adults, it was found that there 
56 
 
was no difference in association between vitamin D intake and insufficient or deficient 
serum 25(OH)D levels in the group at the lower quartile of vitamin D intake compared to 
the group in the upper quartile of vitamin D intake. However, use of supplements was 
not included in the analysis, which may affected the results (6). In addition, a large study 
of a middle-aged Caucasian population also observed no difference in association 
between serum 25(OH)D levels and vitamin D intake when comparing quartiles of 
vitamin D intake (62). 
 
Other studies have, however, found that dietary intake of vitamin D is positively 
associated with serum 25(OH)D level. Several studies conducted in Norway have shown 
that intake of fatty fish and cod liver oil are positively associated with serum 25(OH)D 
levels and inversely associated with prevalence of vitamin D deficiency (63,126). A 
cross-sectional study of a Norwegian adult population found that mean serum 25(OH)D 
level in the participants with daily intake of cod liver oil was 65.5 nmol/L, compared to 
57.9 nmol/L in the participants with no cod liver oil intake (63). In a study of Icelandic 
children, it was also found that current vitamin D intake was positively associated with 
vitamin D status (128). Among the children taking the recommended daily dose of 
vitamin D supplement, 83% had a sufficient level of serum 25(OH)D, while only 51% of 
the children not taking any vitamin D supplement had a sufficient serum 25(OH)D level 
(128). 
 
Optimal 25(OH)D levels 
As sunlight exposure and factors that affect sunlight exposure are important 
determining factors of vitamin D status, it complicates the estimation of daily needed 
vitamin D intake through diet to achieve specific serum 25(OH)D concentrations, and 
there is still lack of consensus as to the daily recommended dose to attain the desired 
level of serum 25(OH)D (16,129). The dietary recommendations for daily vitamin D 
intake are, therefore, estimated based on conditions of minimal sunlight exposure (17). 
In addition, due to the nonlinear dose-response of vitamin D intake on serum 25(OH)D 
levels, it makes it more complicated to estimate the needed daily vitamin D intake 
(16,130). Studies of the dose-response relation between vitamin D intake and serum 
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25(OH)D have shown that the association is dependent on the basal concentration, 
where the response is greater when the basal concentration is low (16,129,131). It has 
been estimated that at low starting serum 25(OH)D levels, the average increase in serum 
25(OH)D is 1.2 nmol/L for every µg of vitamin D3 given as a daily oral dose, while at 
higher starting 25(OH)D levels, the increase is only 0.7 nmol/L or less per µg vitamin D3 
(131).  
 
Other studies looking at the dose-response relationship have found a nonlinear 
relationship between vitamin D intake and serum 25(OH)D levels, with a great increase 
in serum 25(OH)D with dosages up to 25 µg/d, and a flattened response as daily intake 
exceeds 25 µg/d (17). This indicates that increasing a daily vitamin D intake from a very 
low intake to a recommended or slightly higher intake has a greater effect on serum 
25(OH)D levels than increasing a daily vitamin D intake that is already above the 
recommended dose. In addition, several studies observed a higher response of serum 
25(OH)D to total vitamin D intake at lower compared to higher latitudes (>49,5 °N) 
(17,132). Taken together, these findings regarding the dose-response relationship 
between dietary intakes of vitamin D and serum 25(OH)D concentrations have made it 
difficult to estimate a daily vitamin D intake needed to achieve an optimal serum 
25(OH)D level. The suggested daily vitamin D intake needed to achieve optimal serum 
25(OH)D concentrations varies. While some suggest that at least 15 µg/d is needed to 
attain a mean serum 25(OH)D level of 50 nmol/L and at least 20−25 µg/d is needed to 
reach a serum level of 75 nmol/L (131), others suggest that the daily intake should be 
25−50 µg or even higher to maintain serum 25(OH)D levels that are optimal for health 
(133,134).   
 
In summary, the results from this and previous studies indicate that dietary intake of 
vitamin D is one of the significant determinants of serum 25(OH)D level, and that a 
habitual diet containing vitamin D-rich food items contributes to attain a sufficient level 





5.3.3 Anthropometric measurements 
We found that serum 25(OH)D levels were negatively related to BMI and waist 
circumference. These findings are in line with several previous studies showing that 
overweight was associated with lower 25(OH)D concentrations (135–137). A meta-
analysis of observational studies found that the prevalence of vitamin D deficiency was 
35% higher in obese subjects compared to the normal weight group (135). In addition, a 
meta-analysis of 21 cohorts observed an inverse association between serum 25(OH)D 
and BMI, where each unit increase in BMI was associated with 1.15% lower serum 
25(OH)D concentrations (136). Similar results was found in an observational study of 
250 adults, where BMI was inversely associated with serum 25(OH)D, and each unit 
increase in BMI was associated with a decrease of 0.74 nmol/L serum 25(OH)D (137). 
These associations between serum 25(OH)D and anthropometric measurements have 
also been observed in several observational studies from the Nordic countries, showing 
that overweight and obesity is associated with increased risk of insufficient serum 
25(OH)D levels (6,7,138). 
 
Several hypotheses explaining the observed association between overweight and 
vitamin D status have been suggested. One potential explanation is that overweight and 
obesity are associated with other factors, such as inactivity and limited outdoor activity, 
causing insufficient sunlight exposure and thereby a low production of vitamin D3 in the 
skin (139,140). However, previous studies have shown that serum 25(OH)D levels are 
lower in obese individuals compared to normal weight individuals despite similar 
sunlight exposure, and that the increase of 25(OH)D levels in obese subjects are 
significantly lower than in normal weight subjects when exposed to identical amount of 
UV-B radiation (141). A suggested explanation to the differences in vitamin D status 
between obese and normal weight individuals is that vitamin D3 is sequestered in 
subcutaneous fat, and because obese subjects have more fat available for this process, 
the serum levels of 25(OH)D are therefore lower (139–141).  
 
Another hypothesized explanation is that volumetric dilution makes up the observed 
differences of vitamin D status in obese compared to normal weight individuals 
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(139,140,142). According to this hypothesis, the low serum 25(OH)D levels in obese 
individuals are explained by the larger body size, meaning that putting the same amount 
into a larger pool, will result in a lower concentration (139,140,142). It has therefore 
been suggested that vitamin D dosage to treat deficiency should be adjusted according to 
body weight to supply a sufficient amount (142).  
 
Taken together, the results from the present thesis, are in line with several previous 
findings, indicating that increasing body weight is inversely associated with serum 
25(OH)D levels, and may potentially be one of the determining factors of vitamin D 
status.   
 
5.3.4 Lifestyle 
Closely related to sunlight exposure, diet, and bodyweight, it has been suggested that the 
lifestyle of an individual is one of the determining factors of vitamin D status. Previous 
studies have found vitamin D status to be associated with lifestyle factors such as degree 
of outdoor activity, exercise, and clothing style (6,7,62,65). A lifestyle characterized by 
limited physical activity, minimal time outdoors, and a clothing style that includes 
covering most of the skin, has been shown to be associated with significantly lower 
serum 25(OH)D levels (6,7,62,65). Data from The Tromsø Study looking at vitamin D 
status in Norwegian adolescents, showed that some of the lifestyle factors related to 
serum 25(OH)D levels were use of snuff, physical activity, sunbathing holiday, and use of 
solarium (143). The effects of lifestyle on vitamin D status is largely explained by the 
associations between lifestyle and sunlight exposure, healthy diet, and bodyweight, 
which are important determinants of vitamin D status.  
 
5.3.5 Standard lipids 
In this study, HDL-C was found to be positively associated with serum 25(OH)D level, 
while an inverse relationship was observed between 25(OH)D and TGs. Several previous 
studies also found that 25(OH)D associated positively with HDL-C (144,145) and 
inversely with TGs (144–146). In a study of patients referred for the diagnosis and 
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treatment of hyperlipidemia and CVD, serum 25(OH)D was positively associated with 
HDL-C, with a Spearman`s rho of 0.19, and inversely associated with TGs, with a 
Spearman`s rho of −0.25 (144). This shows similar, but stronger associations between 
serum 25(OH)D and the lipids, as in the current thesis. In a cross-sectional study from 
the University of Tromsø including 10105 subjects, it was found an increase in total 
cholesterol, HDL-C, and LDL-C, and a decrease in LDL-C/HDL-C ratio and TGs across 
increasing serum 25(OH)D concentrations (145). The strongest associations were 
observed for HDL-C and TGs with a difference of 6.0 and 18.5% between the lowest and 
highest quartile of serum 25(OH)D. The results in the current thesis are similar to these 
previous findings, where HDL-C was positively and TGs inversely associated with serum 
25(OH)D.  
 
Based on the observed associations between vitamin D status and several of the 
standard lipids, it has been suggested a relationship between serum 25(OH)D levels and 
cardiovascular health, which has also been observed in several previous studies (33–
35). In several trials, it was observed that changes in serum lipids were small and the 
effect of vitamin D supplementation on lipid concentrations did not differ from the 
placebo group (147,148). A meta-analysis found that vitamin D supplementation was 
related to an increase in LDL-C and a small increase in total cholesterol, while HDL-C and 
TGs were slightly reduced (149). Another systematic review and meta-analysis showed 
that vitamin D supplementation reduced serum levels of total cholesterol, LDL-C, and 
TGs (150). Thus, the long-term effects of vitamin D supplementation on the lipid profile 
and risk of CVD are still uncertain. 
 
Taken together, the results from this thesis, and previous studies, indicate a relationship 
between vitamin D status and the standard lipid profile. However, these associations are 
still non fully elucidated, and further work is needed to investigate the connection 
between vitamin D status, possible causal pathways, effects of vitamin D 





5.3.6 Glycemic control 
We observed a negative relationship between vitamin D status and serum glucose, 
HbA1c, and type 2 diabetes diagnosis. The observed association between serum 
25(OH)D level and glycemic control have also been found in several previous studies 
(151–154). A cross-sectional study of postmenopausal women showed that fasting 
serum glucose was inversely associated with serum 25(OH)D, with a Pearson`s 
correlation coefficient of −0.15 (151). In addition, a study of young men and women 
found an inverse association between fasting plasma glucose and serum 25(OH)D (152). 
In a cohort of 7198 Caucasian subjects, it was found an inverse relationship between 
serum 25(OH)D and HbA1c (153). Similar results were found in a large cohort of adults 
over the age of 20 years, showing that lower levels of serum 25(OH)D were associated 
with higher HbA1c (154). Previous studies have also investigated the effects of vitamin 
D supplementation on glycemic control (155,156). A meta-analysis of 47 randomized 
controlled trials (RCTs) including nondiabetic adults found a weak positive effect, where 
vitamin D supplementation reduced fasting glucose by 0.11 mmol/L (155). Another 
meta-analysis of RCTs showed a summary mean difference in fasting glucose between 
the intervention and placebo group of −0.12 mmol/L (156). These findings indicate a 
potential beneficial effect of vitamin D supplementation of serum glucose. However, the 
effects of vitamin D supplementation on glycemic control and risk of diabetes is still not 
fully elucidated.  
 
Based on observed associations between vitamin D status and glucose homeostasis, it 
has been suggested that vitamin D status could be associated with diabetes risk (1,157). 
A meta-analysis of 13 cross-sectional studies found that patients with type 1 diabetes 
had lower serum 25(OH)D levels than the control group, and that there was an 
association between vitamin D deficiency and type 1 diabetes (157). Similar findings 
have been observed when looking at type 2 diabetes, showing that 25(OH)D was 
inversely related to risk of type 2 diabetes (158,159). A meta-analysis of 21 prospective 
studies found an inverse association between serum 25(OH)D and risk of type 2 
diabetes, where the relative risk of type 2 diabetes when comparing the highest to 
lowest category of 25(OH)D levels was 0.62 (158). In addition, a meta-analysis of 8 
observational studies observed a 43% lower risk of developing type 2 diabetes among 
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the individuals with the highest vitamin D status (above 62.5 nmol/L) compared to the 
subjects in the group with the lowest vitamin D status (under 35 nmol/L)(159). The 
results from the current thesis are in line with these findings, indicating an association 
between serum 25(OH)D and type 2 diabetes.  
 
The observed associations between serum 25(OH)D levels and circulating markers of 
glycemic control in this thesis, and the relationship between vitamin D and beta-cell 
function and insulin sensitivity observed in previous studies (152,160,161), indicate 
that this relationship may be of clinical significance, and should be further investigated 
in future studies.  
 
5.3.7 Inflammation 
A weak inverse association was observed between serum 25(OH)D level and the 
inflammatory markers CRP and neopterin at lower serum levels of 25(OH)D, and these 
associations seemed to be reduced at higher 25(OH)D levels. Similar results have been 
found in a large cross-sectional study of an adult population, where it was observed an 
inverse relation between serum 25(OH)D and CRP at 25(OH)D levels below the median 
(52.5 nmol/L), while a positive association was observed at serum 25(OH)D levels 
above the median, equivalent to a geometric mean CRP change of 0.06 mg/L for each 1 
nmol/L change in serum 25(OH)D (162). Similarly, a cross-sectional study of a general 
adult population observed a U-shaped relationship between vitamin D status and high 
sensitivity-CRP (hs-CRP) (163). It was found that hs-CRP concentrations decreased up to 
a 25(OH)D concentration of about 52.5 nmol/L and increased when the 25(OH)D 
concentrations exceeded 62.5 nmol/L (163). In addition, an inverse relationship 
between serum 25(OH)D and CRP was observed in a cross-sectional study of an elderly 
population, where the lowest quartile of 25(OH)D was associated with higher CRP 
compared to the upper quartile (OR = 1.23) (164). When looking at the effects of vitamin 
D supplementation, pooled data from four RCTs investigating the effects of vitamin D 
supplementation in subjects without vitamin D deficiency found a slight increase in hs-
CRP in the subjects given vitamin D supplement (delta value = 0.02 mg/L) whereas in 
the placebo group there was a slight decrease (165). However, a meta-analysis of RCTs 
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evaluating the impact of vitamin D supplementation on CRP found a weighted mean 
difference in CRP of −0.26 mg/L following administration of vitamin D (166). The 
association between serum 25(OH)D and CRP observed in this thesis and previous 
studies, indicate a potential nonlinear relationship. However, this relation, and the 
effects of vitamin D supplementation on inflammatory markers, are still not fully 
elucidated.  
 
Based on observed associations between vitamin D status and inflammatory markers, it 
has been suggested that vitamin D status may be related to risk of infectious and 
autoimmune diseases like tuberculosis, rheumatoid arthritis, and type 1 diabetes 
(1,167,168). A high prevalence of insufficient serum 25(OH)D levels has been found in 
subjects with these infectious and autoimmune diseases (14). Future studies should 
further investigate the mechanisms of the association between serum 25(OH)D and 




Serum 25(OH)D concentration was found to be positively associated with riboflavin, 
pyridoxal phosphate, 4-pyridoxic acid, folate, cobalamin, vitamin A, and vitamin E in the 
present study. These associations may be explained by interacting effects of the 
vitamins, that other vitamins may have functions affecting the metabolism or actions of 
vitamin D (169,170), or the fact that the fat-soluble vitamins have similar absorption, 
transport, and storage mechanisms (9).  
 
B vitamins 
The positive association between serum levels of 25(OH)D and pyridoxal phosphate, the 
active form of vitamin B6, was the strongest observed relationship among the B 
vitamins. There is not much previous data on the association between serum 25(OH)D 
and PLP, although a cross-sectional study on community-dwelling middle-aged and 
older people showed that vitamin B6 was positively associated with serum 25(OH)D 
64 
 
concentration, with a partial Pearson`s r of 0.35 for women and 0.21 for men (171). It 
has been suggested that PLP may have modulatory effects on the action of steroid 
hormones, including calcitriol, which may partly explain the observed association 
between serum 25(OH)D and PLP (169,172). The associations between serum levels of 
25(OH)D and the B vitamins included in our analyses were weak, and existing evidence 
does not provide any conclusive data supporting a clinically significant association 
between vitamin D status and circulating levels of B vitamins. Thus, the connection is 
still highly uncertain. 
 
Fat-soluble vitamins 
In a large cohort of adults above 35 years of age examining vitamin D levels by quartiles, 
serum levels of vitamin A and vitamin E were positively associated with serum 25(OH)D 
(64). The common mechanisms involved in the metabolism of the fat-soluble vitamins 
may partly explain why 25(OH)D was associated with vitamin A and E. Another 
potential connection, is the observed interactions between vitamin D and vitamin A, 
where high concentrations of 9-cis retinoic acid, a vitamin A metabolite, may prevent 
calcitriol to perform its gene regulatory functions (170,173). Our observations are in 
line with existing knowledge and previously observed connections between serum 
25(OH)D and other fat-soluble vitamins.  
 
5.3.9 Amino acids 
The plasma concentration of several amino acids appeared to correlate with serum 
25(OH)D. Sarcosine and choline associated positively with 25(OH)D, while an inverse 
relationship was found for total homocysteine at lower levels of 25(OH)D, but this 
association appeared to be weaker at higher serum levels of 25(OH)D. The relationship 
between 25(OH)D and homocysteine was the strongest observed association among 
amino acids in our data. A similar relationship was also observed in a large community-
based cohort of asymptomatic adults, where they found an inverse association between 
homocysteine and serum 25(OH)D at 25(OH)D levels below median (52.5 nmol/L), 
while a weak positive association was observed at 25(OH)D levels above median level 
(174). A longitudinal study of 4475 participants showed that baseline homocysteine 
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concentrations were inversely associated with serum 25(OH)D, where homocysteine 
concentrations were 0.182 µmol/L lower for each additional 25 nmol/L of serum 
25(OH)D concentration (175). However, when the analyses were repeated separately by 
subgroup of baseline 25(OH)D, it was observed that each additional 25 nmol/L 25(OH)D 
was associated with 1.056 µmol/L lower homocysteine in the subjects with 25(OH)D 
below 50 nmol/L and 0.150 µmol/L in those with serum 25(OH)D above 50 nmol/L 
(175). A quite similar trend was found in the current thesis, where the inverse 
association between serum 25(OH)D and homocysteine was weaker at higher levels of 
serum 25(OH)D.  
 
The observed associations between serum levels of 25(OH)D and different amino acids 
were weak in our population, and the results from previous studies are inconclusive. 
However, a relationship between vitamin D and homocysteine, similar to the observed 
association in the current thesis, has been found in previous studies (174,175), 
indicating that this relationship may be of clinical significance, and should be further 





6 Future perspectives 
The prevalence of suboptimal vitamin D status is still high, both in Norway and 
worldwide (8,23). Insufficient vitamin D status is associated with health risks, and 
prevention of vitamin D deficiency is a public health priority (23,176). Thus, research 
into the determinants of vitamin D status is vital to get a better understanding of the 
causes of insufficient vitamin D status, and thereby improving strategies to prevent 
vitamin D deficiency.  
 
Due to the nature of the study design in the present study, we are not able to draw any 
conclusions on causal relationships. However, the results from this and previous studies 
indicate associations between serum 25(OH)D level and season, vitamin D intake, lipid 
profile, PLP, vitamin A, vitamin E, BMI, and glucose metabolism. These observations may 
be the basis of future studies further investigating the associations between serum 
25(OH)D and the different variables. Longitudinal studies allows us to measure the 
characteristics of the same individuals on several occasions over time, and may be used 
to evaluate the relationship between the potential determinants and serum levels of 
25(OH)D over time (177,178). These types of studies have the ability to demonstrate 
temporality, and cause-and-effect relationships can be examined for the associations 
between serum 25(OH)D levels and different variables already observed (177,179). As 
mentioned, vitamin D status is affected by seasonal variation, which makes the 
assessment of associations between serum 25(OH)D and potential determinants more 
complicated. A suggested method to deal with seasonality of 25(OH)D is cosinor 
modelling (122), which could provide a more precise estimate of the associations 
between serum 25(OH)D and different determinants. Further, interventional studies, 
where a potential determinant of vitamin D status is changed and the effects on serum 
levels of 25(OH)D are measured, can be conducted to assess determinants of vitamin D 





In this study, we explored a wide variety of factors to investigate associations with 
serum 25(OH)D level, aiming to get a deeper understanding of potential determinants of 
vitamin D status. In conclusion, we observed a seasonal variation of serum 25(OH)D, 
where the highest concentrations were measured in August, and the lowest 
concentrations were measured in March. Serum levels of 25(OH)D were positively 
associated with dietary vitamin D, fish and egg consumption, and with serum levels of 
HDL-C, PLP, vitamin A, and vitamin E. Inverse associations were observed for BMI, and 
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1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the unadjusted regression model. 
BMI, body mass index (kg/m2); eGFR, estimated glomerular filtration ratio; season 1, January-March; season 2, April-June; season 3, July-September; season 4, October-
December. 
 





0.10 0.25 0.50 0.75 0.90 
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
Age (years) −0.16 (−0.24, −0.09) <0.001 −0.00 (−0.07, 0.07) 0.947 0.19 (0.12, 0.26) <0.001 0.41 (0.43, 0.48) <0.001 0.62 (0.54. 0.69) <0.001 
Sex (1 = male) 1.09 (−1.39, 3.57) 0.383 1.62 (−0.44, 3.68) 0.120 1.47 (−0.31, 3.25) 0.103 0.68 (−1.29, 2.64) 0.493 −1.50 (−4.25, 1.25) 0.279 
BMI (kg/m2) −1.55 (−1.70, −1.42) <0.001 −1.20 (−1.33, −1.07) <0.001 −0.77 (−0.90, −0.65) <0.001 −0.27 (−0.40, −0.13) <0.001 0.20 (0.01, 0.32) 0.003 
Current smoker 
(n) 
−6.12 (−8.02, −4.21) <0.001 −5.65 (−7.05, −4.24) <0.001 −3.22 (−5.04, −1.41) <0.001 −0.83 (−2.48, 0.82) 0.317 −1.53 (−4.63, 1.57) 0.325 
eGFR (mL/min 
per 1,732) 




−0.44 (−0.50, −0.38) <0.001 −0.34 (−0.40, −0.27) <0.001 −0.20 (−0.27, −0.14 <0.001 −0.06 (−0.12, 0.00) 0.050 0.00 (0.00, 0.13) 0.050 
Vitamin D 
intake (µg/d) 
0.39 (0.19, 0.59) <0.001 0.29 (0.10, 0.47) 0.003 0.42 (0.30, 0.55) <0.001 0.45 (0.25, 0.65) <0.001 0.51 (0.18, 0.85) 0.003 
Season 1 −6.65 (−9.41, −3.89) <0.001 −9.30 (−11.2, −7.39) <0.001 −10.3 (−11.9, −8.66) <0.001 −10.3 (−13.3, −7.20) <0.001 −8.99 (−13.1, −4.85) <0.001 
Season 2 0.10 (−2.58, 2.79) 0.939 1.25 (−1.22, 3.71) 0.314 0.06 (−1.45, 1.57) 0.936 −1.10 (−3.79, 1.59) 0.414 −0.79 (−4.73, 3.14) 0.688 
Season 3 10.9 (8.25, 13.6) <0.001 12.4 (9.81, 14.9) <0.001 12.6 (9.76, 15.4) <0.001 11.0 (8.41, 13.5) <0.001 9.31 (6.36, 12.3) <0.001 




1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the unadjusted regression model. 
TG, serum triglycerides; HDL-C, serum high density lipoprotein cholesterol; LDL-C, serum low density lipoprotein cholesterol; ApoA1, Apolipoprotein A1; ApoB, 
Apolipoprotein B; HbA1c, glycosylated haemoglobin; CRP, C-reactive protein. 
 
Supplementary table 2. Associations between 25(OH)D levels and lipid profile, blood glucose and inflammatory markers in selected quantiles of 25(OH)D levels from the 
unadjusted regression model.1 
Variable 
Quantile 
0.10 0.25 0.50 0.75 0.90 
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
TG (mmol/L) −1.66 (−2.17, −1.14) <0.001 −2.08 (−2.79, −1.37) <0.001 −1.96 (−2.60, −1.32) <0.001 −1.24 (−2.27, −0.21) 0.019 −1.19 (−2.10, 0.28) 0.011 
Total cholesterol 
(mmol/L) 
−1.16 (−1.89, −0.43) 0.003 −1.04 (−1.99, −0.09) 0.032 −0.38 (−0.89, 0.13) 0.139 0.40 (−0.47, 1.26) 0.361 1.32 (0.01, 2.63) 0.049 
LDL-C (mmol/L) −0.66 (−1.53, 0.20) 0.128 −1.21 (−2.18, −0.24) 0.016 −0.48 (−1.27, 0.31) 0.228 0.93 (0.06, 1.80) 0.037 0.68 (−0.95, 2.31) 0.406 
HDL-C (mmol/L) 5.44 (2.91, 7,97) <0.001 6.31 (3.87, 8.76) <0.001 6.50 (4.96, 8.05) <0.001 7.03 (5.09, 8.96) <0.001 7.30 (4.98, 9.61) <0.001 
Non-HDL-C 
(mmol/L) 
−1.04 (−1.73, −0.34) 0.004 −1.35 (−2.35, −0.35) 0.009 −1.20 (−1.67, −0.73) <0.001 −0.57 (−1.27, 0.14) 0.111 −0.58 (−2.01, 0.85) 0.419 
ApoA1 (g/L) 7.78 (4.12, 11.45) <0.001 9.62 (6.20, 13.03) <0.001 10.6 (7.66, 13.5) <0.001 11.9 (8.12, 15.77) <0.001 11.7 (6.89, 16.5) <0.001 
ApoB (g/L) −3.44 (−6.68, −0.19) 0.039 −3.66 (−7.02, −0.30) 0.033 −3.02 (−6.61, 0.56) 0.096 −0.67 (−3.26, 1.93) 0.608 0.37 (−5.59, 6.34) 0.901 
Type 2 diabetes 
(n) 
−5.33 (−8.11, −2.54) <0.001 −3.58 (−6.12, −1.05) 0.007 −2.66 (−4.41, −0.91) 0.004 −3.45 (−6.66, −0.24) 0.036 −0.28 (−4.19, 3.64) 0.887 
HbA1c (%) −1.81 (−3.13, −0.50) 0.008 −1.90 (−2.73, −1.07) <0.001 −1.14 (−1.70, −0.57) <0.001 −0.56 (−1.38, 0.25) 0.170 −0.01 (−1.52, 1.51) 0.999 
Serum glucose 
(mmol/L) 
−1.26 (−1.64, −0.88) <0.001 −1.07 (−1.65, −0.49) <0.001 −0.75 (−1.06, −0.44) 0.001 −0.36 (−0.76, 0.05) 0.083 −0.05 (−0.65, 0.56) 0.882 
CRP (mg/L) −0.24 (−0.37, −0.11) <0.001 −0.23 (−0.38, −0.08) 0.003 −0.22 (−0.37, −0.08) 0.003 −0.04 (−0.23, 0.14) 0.652 −0.01 (−0.10, 0.09) 0.887 
Neopterin 
(nmol/L) 




1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the unadjusted regression model. 
PL, Pyridoxine levels; PLP, Pyridoxal 5-phosphate; PA, 4-pyridoxic acid; MMA, methylmalonic acid.  
  
Supplementary table 3. Associations between 25(OH)D levels and dietary data in selected quantiles of 25(OH)D levels from the unadjusted regression model.1 
Variable 
Quantile 
0.10 0.25 0.50 0.75 0.90 
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
Riboflavin 
(µg/dL)  
−0.02 (−0.07, 0.02) 0.329 0.01 (−0.06, 0.09) 0.721 0.04 (0.02, 0.05) <0.001 0.17 (0.05, 0.29) 0.005 0.12 (−0.05, 0.30) 0.157 
PL (nmol/L) −0.02 (−0.03, 0.00) 0.055 0.00 (−0.00, 0.01) 0.147 0.01 (−0.00, 0.01) 0.095 0.01 (−0.04, 0.07) 0.629 0.08 (0.00, 0.15) 0.04 
PLP (nmol/L) −0.16 (−0.22, −0.10) <0.001 −0.08 (−0.11, −0.04) <0.001 0.02 (0.00, 0.03) 0.025 0.16 (0.12, 0.20) <0.001 0.35 (0.26, 0.45) <0.001 
PA (nmol/L) −0.01 (−0.07, 0.05) 0.663 −0.02 (−0.06, 0.03) 0.424 0.00 (0.00, 0.01) 0.009 0.05 (−0.01, 0.11) 0.101 0.12 (−0.10, 0.33) 0.272 
Folate (nmol/L) 0.04 (−0.12, 0.20) 0.615 0.02 (−0.06, 0.09) 0.618 0.07 (0.01, 0.13) 0.035 0.16 (0.06, 0.25) 0.002 0.21 (−0.13, 0.55) 0.225 
Cobalamin 
(pq/mL) 
−0.06 (−0.06, −0.05) <0.001 −0.03 (−0.03, −0.02) <0.001 0.00 (−0.00, 0.00) 0.473 0.03 (0.02, 0.03) <0.001 0.06 (0.06, 0.07) <0.001 
MMA (nmol/L) −6.21 (−18.1, 5.67) 0.298 −0.62 (−8.16, 6.92) 0.870 −1.75 (−8.49, 4.99) 0.604 1.78 (−6.20, 9.77) 0.656 4.36 (−16.6, 25.4) 0.678 
Vitamin A 
(µmol/L) 
2.20 (0.40, 5.08) 0.018 3.67 (2.25, 5.08) <0.001 4.25 (3.09, 5.41) <0.001 5.14 (3.56, 6.71) <0.001 7.95 (6.23, 9.68) <0.001 
Vitamin E 
(µmol/L) 
−0.45 (−0.55, −0.36) <0.001 −0.16 (−0.25, −0.07) <0.001 0.21 (0.11, 0.31) <0.001 0.65 (0.55, 0.75) <0.001 1.06 (0.95, 1.17) <0.001 
Low fat milk 
consumption 
(g/day) 
−0.07 (−0.08, −0.06) <0.001 −0.04 (−0.04, −0.03) <0.001 −0.00 (−0.01, 0.00) 0.173 0.03 (0.03, 0.04) <0.001 0.08 (0.06, 0.10) <0.001 
Egg consumption 
(g/day) 
−0.07 (−0.21, 0.07) 0.317 −0.01 (−0.19, 0.17) 0.884 −0.01 (−0.11, 0.09) 0.789 0.29 (0.09, 0.50) 0.006 0.37 (0.04, 0.70) 0.030 
Fish consumption 
(g/day) 




1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the unadjusted regression model. 
DMG, plasma dimetylglycine; tHcy, total homocysteine; tCys, total cysteine. 
 




0.10 0.25 0.50 0.75 0.90 
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
Serine (µmol/L)  −0.23 (−0.26, −0.20) <0.001 −0.13 (−0.16, −0.11) <0.001 −0.02 (−0.05, 0.01) 0.187 0.11 (0.09, 0.14) <0.001 0.23 (0.20, 0.26) <0.001 
Glycine 
(µmol/L)  
−0.09 (−0.10, −0.08) <0.001 −0.04 (−0.05, −0.03) <0.001 0.01 (0.00, 0.02) 0.003 0.07 (0.07, 0.08) <0.001 0.13 (0.12, 0.14) <0.001 
Dmg (µmol/L) −0.13 (−0.73, 0.47) 0.657 −0.11 (−0.55, 0.33) 0.627 −0.11 (−0.41, 0.19) 0.453 0.12 (−0.35, 0.60) 0.607 0.08 (−0.10, 1.16) 0.883 
Sarcosine 
(µmol/L)  
2.12 (0.68, 3.56) 0.005 2.47 (1.08, 3.85) <0.001 2.50 (1.26, 3.74) <0.001 3.60 (1.88, 5.33) <0.001 3.82 (1.76, 5.88) <0.001 
Choline 
(µmol/L)  
−0.45 (−1.10, 0.19) 0.162 0.24 (−0.25, 0.73) 0.332 0.68 (0.44, 0.92) <0.001 1.37 (0.91, 1.84) <0.001 2.23 (1.42, 3.04) <0.001 
Betaine 
(µmol/L)  
−0.47 (−0.56, −0.38) <0.001 −0.21 (−0.26, −0.15) <0.001 0.05 (0.01, 0.10) 0.025 0.37 (0.32, 0.43) <0.001 0.70 (0.61, 0.78) <0.001 
Methionine 
(µmol/L)  
−0.61 (−0.75, −0.46) <0.001 −0.27 (−0.38, −0.15) <0.001 0.04 (−0.05, 0.13) 0.337 0.49 (0.39, 0.59) <0.001 0.78 (0.61, 0.94) <0.001 
tHcy (µmol/L) −0.35 (−0.92, 0.22) 0.225 −0.37 (−0.61, −0.12) 0.004 −0.07 (−0.21, 0.08) 0.364 0.32 (−0.12, 0.76) 0.146 0.88 (0.32, 1.44) 0.003 





1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the regression model adjusted for 
age and sex. BMI, body mass index (kg/m2); eGFR, estimated glomerular filtration ratio; waist circ., waist circumference; season 1, January-March; season 2, April-June; 
season 3, July-September; season 4, October-December. 
Supplementary table 5. Associations between 25(OH)D levels and demographic characteristics in selected quantiles of 25(OH)D levels derived from a regression 
model adjusted for age and sex.1 
 Quantile 
0.10 0.25 0.50 0.75 0.90 
Variable 
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
BMI (kg/m2) −1.01 (−1.17, −0.85) <0.001 −0.86 (−1.00, −0.71) <0.001 −0.68 (−0.82, −0.54) <0.001 −0.58 (−0.71, −0.44) <0.001 −0.36 (−0.58, −0.14) 0.002 
Current smoker 
(n) 
−1.88 (−3.26, −0.50) 0.009 −1.88 (−3.21, −0.54) 0.007 −1.75 (−3.10, −0.40) 0.012 −1.72 (−3.08, −0.36) 0.014 −1.47 (−2.84, −0.10) 0.036 
eGFR (mL/min 
per 1,732) 
−0.27 (−0.34, −0.20) <0.001 −0.23 (−0.28, −0.17) <0.001 −0.16 (−0.22, −0.10) <0.001 −0.07 (−0.13, −0.02) 0.013 −0.05 (−0.11, 0.02) 0.137 
Waist circ. (cm) −0.36 (−0.42, −0.30) <0.001 −0.33 (−0.39, −0.26) <0.001 −0.24 (−0.30, −0.18) <0.001 −0.14 (−0.21, −0.07) <0.001 −0.07 (−0.16, 0.01) 0.087 
Season 1 −9.20 (−10.9, −7.49) <0.001 −9.24 (−11.0, −7.53) <0.001 −9.24 (−11.0, −7.53) <0.001 −9.24 (−11.0, −7.52) <0.001 −9.24 (−10.9, −7.52) <0.001 
Season 2 −0.18 (−1.66, 1.29) 0.805 −0.18 (−1.65, 1.29) 0.807 −0.18 (−1.65, 1.29) 0.808 −0.18 (−1.66, 1.30) 0.809 −0.18 (−1.64, 1.29) 0.808 
Season 3 11.7 (9.78, 13.7) <0.001 11.7 (9.78, 13.7) <0.001 11.7 (9.79, 13.7) <0.001 11.7 (9.79, 13.7) <0.001 11.7 (9.78, 13.7) <0.001 
Season 4 −0.61 (−2.13, 0.91) 0.425 −0.61 (−2.13, 0.90) 0.419 −0.61 (−2.13, 0.90) 0.420 −0.61 (−2.13, 0.91) 0.421 −0.62 (−2.13, 0.90) 0.418 
Vitamin D 
intake (µg/d) 
0.42 (0.29, 0.56) <0.001 0.45 (0.35, 0.56) <0.001 0.48 (0.38, 0.59) <0.001 0.49 (0.35, 0.63) <0.001 0.50 (0.35, 0.64) <0.001 
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Supplementary table 6. Associations between 25(OH)D levels and lipid profile, blood glucose and inflammatory markers in selected quantiles of 25(OH)D levels 
derived from a regression model adjusted for age and sex.1 
 Quantile 
0.10 0.25 0.50 0.75 0.90 
Variable 
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
TG (mmol/L) −1.89 (−2.45, −1.32) <0.001 −1.69 (−2.19, −1.19) <0.001 −1.49 (−1.97, −1.00) <0.001 −1.46 (−1.98, −0.95) <0.001 −0.85 (−1.50, −0.21) 0.011 
Total cholesterol 
(mmol/L) 
−0.23 (−1.07, 0.61) 0.589 −0.61 (−1.22, 0.00) 0.052 0.06 (−0.46, 0.58) 0.817 0.16 (−0.41, 0.73) 0.584 0.90 (0.01, 1.78) 0.047 
LDL-C (mmol/L) −0.34 (−1.11, 0.43) 0.374 −0.11 (−0.79, 0.56) 0.738 0.07 (−0.60, 0.73) 0.841 0.12 (−0.55, 0.79) 0.720 0.72 (−0.02, 1.47) 0.057 
HDL-C (mmol/L) 7.00 (5.41, 8.59) <0.001 7.08 (5.48, 8.68) <0.001 7.09 (5.50, 8.68) <0.001 7.10 (5.49, 8.70) <0.001 7.19 (5.49, 8.78) <0.001 
Non-HDL-C 
(mmol/L) 
−1.84 (−2.60, −1.08) <0.001 −0.63 (−1.25, −0.02) 0.042 −0.62 (−1.12, −0.12) 0.016 −0.45 (−0.95, 0.06) 0.082 0.31 (−0.45, 1.08) 0.416 
ApoA-I (g/L) 12.06 (9.67, 14.45) <0.001 12.07 (9.65, 14.48) <0.001 12.07 (9.67, 14.47) <0.001 12.13 (9.72, 14.54) <0.001 12.08 (9.68, 14.49) <0.001 
ApoB (g/L) −0.84 (−3.40, 1.72) 0.513 −0.64 (−3.16, 1.88) 0.612 −0.64 (−3.15, 1.88) 0.614 −0.63 (−3.15, 1.89) 0.617 −0.60 (−3.16, 1.95) 0.638 
Type 2 diabetes −4.10 (−6.10, −2.09) <0.001 −4.11 (−6.11, −2.10) <0.001 −4.09 (−6.10, −2.09) <0.001 −4.10 (−6.11, −2.09) <0.001 −4.09 (−6.10, −2.08) <0.001 
HbA1c (%) −2.34 (−3.00, −1.68) 0.008 −1.39 (−2.02, −0.76) <0.001 −1.02 (−1.53, −0.50) <0.001 −0.91 (−1.52, −0.31) 0.004 0.20 (−0.70, 1.11) 0.652 
Serum glucose 
(mmol/L) 
−1.28 (−1.67, −0.88) <0.001 −0.91 (−1.30, −0.53) <0.001 −0.67 (−0.96, −0.38) <0.001 −0.44 (−0.78, −0.10) 0.012 −0.03 (−0.49, 0.43) 0.902 
CRP (mg/L) −0.28 (−0.41, −0.16) <0.001 −0.25 (−0.35, −0.14) <0.001 −0.19 (−0.31, −0.06) 0.004 −0.05 (−0.22, 0.12) 0.559 −0.02 (−0.11, 0.07) 0.601 
Neopterin 
(nmol/L) 
−0.19 (−0.43, 0.05) 0.123 −0.11 (−0.31, 0.09) 0.275 0.06 (−0.08, 0.20) 0.394 0.10 (−0.06, 0.25) 0.210 0.23 (0.10, 0.36) 0.001 
 
1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the regression model adjusted for 
age and sex. TG, serum triglycerides; HDL-C, serum high density lipoprotein cholesterol; LDL-C, serum low density lipoprotein cholesterol; ApoA-I, Apolipoprotein A1; ApoB, 
Apolipoprotein B; HBA1c, glycosylated haemoglobin; CRP, C-reactive protein. 
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Supplementary table 7. Associations between 25(OH)D levels and vitamin status and dietary data in selected quantiles of 25(OH)D levels derived from a regression 
model adjusted for age and sex.1 
 Quantile 
0.10 0.25 0.50 0.75 0.90 
Variable 
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
Riboflavin (µg/dL)  −0.04 (0.00, 0.07) 0.046 0.05 (0.03, 0.08) <0.001 0.04 (0.03, 0.06) <0.001 0.03 (−0.00, 0.06) 0.056 0.07 (0.01, 0.13) 0.029 
PL (nmol/L) 0.00 (−0.01, 0.02) 0.715 0.01 (−0.00, 0.02) 0.175 0.01 (0.00, 0.02) 0.002 0.01 (0.00, 0.01) 0.021 −0.00 (−0.03, 0.03) 0.981 
PLP (nmol/L) 0.01 (−0.02, 0.03) 0.578 0.02 (0.01, 0.04) 0.010 0.04 (0.03, 0.05) <0.001 0.03 (0.01, 0.06) 0.003 0.07 (0.04, 0.10) <0.001 
PA (nmol/L) 0.00 (−0.01, 0.01) 0.662 0.01 (0.00, 0.01) 0.005 0.01 (0.00, 0.01) 0.001 0.01 (0.00, 0.01) 0.030 0.00 (−0.02, 0.03) 0.912 
Folate (nmol/L) 0.06 (0.00, 0.12) 0.046 0.07 (0.00, 0.13) 0.042 0.11 (0.04, 0.18) 0.002 0.14 (0.06, 0.21) <0.001 0.16 (0.06, 0.27) 0.004 
Cobalamin (pq/mL) −0.00 (−0.01, 0.00) 0.395 0.00 (−0.00, 0.01) 0.437 0.00 (−0.00, 0.00) 0.501 0.01 (0.00, 0.02) 0.030 0.02 (0.01, 0.02) 0.001 
MMA (nmol/L) −1.74 (−7.51, 4.04) 0.549 −1.73 (−7.51, 4.05) 0.550 −1.73 (−7.51, 4.05) 0.550 −1.73 (−7.51, 4.05) 0.550 −1.73 (−7.51, 4.05) 0.550 
Vitamin A (µmol/L) 3.03 (1.66, 4.39) <0.001 4.53 (3.64, 5.43) <0.001 4.59 (3.71, 5.46) <0.001 4.60 (3.73, 5.48) <0.001 4.78 (3.72, 5.85) <0.001 
Vitamin E (µmol/L) −0.09 (−0.20, 0.01) 0.080 0.11 (−0.01, 0.24) 0.073 0.26 (0.15, 0.37) <0.001 0.45 (0.31, 0.59) <0.001 0.63 (0.45, 0.82) <0.001 
Low fat milk 
consumption 
(g/day) 
−0.00 (−0.01, −0.00) 0.018 −0.01 (−0.01, 0.00) 0.114 0.00 (−0.00, 0.01) 0.630 0.01 (−0.00, 0.01) 0.087 0.01 (0.00, 0.02) 0.019 
Egg consumption 
(g/day) 
−0.03 (−0.11, 0.04) 0.377 0.02 (−0.08, 0.12) 0.671 0.02 (−0.08, 0.13) 0.666 0.14 (0.03, 0.25) 0.017 0.22 (0.04, 0.40) 0.017 
Fish consumption 
(g/day) 
0.01 (−0.00, 0.03) 0.102 0.03 (0.01, 0.04) 0.003 0.02 (0.01, 0.04) 0.004 0.04 (0.02, 0.06) <0.001 0.03 (0.01, 0.05) 0.018 
 
1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the regression model adjusted for 
age and sex. PL, Pyridoxine levels; PLP, Pyridoxal 5-phosphate; PA, 4-pyridoxic acid; MMA, methylmalonic acid.  
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Supplementary table 8. Associations between 25(OH)D levels and amino acids and amino acid metabolites in selected quantiles of 25(OH)D levels derived from a 
regression model adjusted for age and sex.1 
 Quantile 
0.10 0.25 0.50 0.75 0.90 
Variable 
Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value Estimate (95% CI) P-value 
Serine (µmol/L)  −0.12 (−0.16, −0.08) <0.001 −0.05 (−0.08, −0.02) 0.004 −0.01 (−0.03, 0.02) 0.647 0.06 (0.03, 0.09) <0.001 0.14 (0.10, 0.19) <0.001 
Glycine (µmol/L)  −0.02 (−0.03, −0.01) <0.001 0.00 (−0.01, 0.01) 0.454 0.02 (0.01, 0.03) <0.001 0.06 (0.04, 0.07) <0.001 0.07 (0.05, 0.09) <0.001 
DMG (µmol/L) −0.45 (−0.86, −0.04) 0.033 −0.27 (−0.58, 0.04) 0.086 −0.12 (−0.34, 0.11) 0.304 0.01 (−0.23, 0.25) 0.945 0.23 (−0.20, 0.65) 0.285 
Sarcosine 
(µmol/L)  
2.23 (1.20, 3.26) <0.001 2.45 (1.47, 3.42) <0.001 2.50 (1.51, 3.48) <0.001 2.51 (1.55, 3.47) <0.001 2.54 (1.54, 3.54) <0.001 
Choline (µmol/L)  −0.22 (−0.65, 0.21) 0.312 0.36 (−0.01, 0.74) 0.058 0.55 (0.28, 0.82) <0.001 0.73 (0.42, 1.04) <0.001 1.31 (0.76, 1.86) <0.001 
Betaine (µmol/L)  −0.07 (−0.14, −0.01) 0.029 −0.01 (−0.06, 0.04) 0.731 0.06 (0.01, 0.10) 0.010 0.13 (0.07, 0.19) <0.001 0.18 (0.09, 0.27) <0.001 
Methionine 
(µmol/L)  
−0.22 (−0.35, −0.10) <0.001 −0.03 (−0.12, 0.06) 0.489 0.06 (−0.03, 0.15) 0.172 0.24 (0.12, 0.35) <0.001 0.34 (0.18, 0.49) <0.001 
tHcy (µmol/L) −0.38 (−0.57, −0.19) <0.001 −0.33 (−0.46, −0.20) <0.001 −0.10 (−0.27, 0.06) 0.217 0.14 (−0.11, 0.39) 0.252 0.36 (0.13, 0.60) 0.003 
tCys (µmol/L) −0.07 (−0.08, −0.06) <0.001 −0.03 (−0.05, −0.02) <0.001 0.00 (−0.01, 0.02) 0.492 0.05 (0.03, 0.06) <0.001 0.09 (0.08, 0.11) <0.001 
 
1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the regression model adjusted for 





1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the regression model adjusted for 
age, sex, BMI, smoking-habits and GFR. TG, serum triglycerides; HDL-C, serum high density lipoprotein cholesterol; LDL-C, serum low density lipoprotein cholesterol; ApoA1, 
Apolipoprotein A1; ApoB, Apolipoprotein B; HBA1c, glycosylated haemoglobin; CRP, C-reactive protein. 
Supplementary table 9. Associations between 25(OH)D levels and waist circumference, lipid profile, blood glucose and inflammatory markers in selected quantiles of 
25(OH)D levels derived from a regression model adjusted for age, sex, BMI, smoking habits and GFR. 1 
 Quantile 
 















−0.10 (−0.23, −0.02) 0.097 −0.08 (−0.21, 0.04) 0.187 −0.03 (−0.15, 0.09) 0.564 0.02 (−0.10, 0.14) 0.736 0.07 (−0.05, 0.20) 0.230 
TG (mmol/L) −1.10 (−1.55, −0.66) <0.001 −1.13 (−1.58, −0.68) <0.001 −1.10 (−1.55, −0.65) <0.001 −1.10 (−1.55, −0.65) <0.001 −1.07 (−1.53, −0.62) <0.001 
Total cholesterol 
(mmol/L) 
0.09 (−0.50, 0.67) 0.771 0.09 (−0.50, 0.68) 0.755 0.11 (−0.47, 0.70) 0.698 0.12 (−0.46, 0.71) 0.674 0.14 (−0.44, 0.73) 0.626 
LDL-C (mmol/L) 0.06 (−0.52, 0.65) 0.826 0.09 (−0.50, 0.68) 0.767 0.10 (−0.49, 0.69) 0.735 0.10 (−0.49, 0.69) 0.725 0.12 (−0.48, 0.71) 0.693 
HDL-C (mmol/L) 6.12 (4.12, 8.13) <0.001 6.13 (4.12, 8.13) <0.001 6.13 (4.12, 8.13) <0.001 6.13 (4.13, 8.14) <0.001 6.14 (4.13, 8.14) <0.001 
Non-HDL-C (mmol/L) −0.46 (−1.01, 0.09) 0.101 −0.45 (−1.00, 0.10) 0.104 −0.43 (−0.99, 0.12) 0.124 −0.43 (−0.98, 0.13) 0.127 −0.41 (−0.97, 0.14) 0.143 
ApoA1 (g/L) 10.96 (8.32, 13.60) <0.001 10.97 (8.33, 13.60) <0.001 10.97 (8.33, 13.61) <0.001 10.97 (8.34, 13.61) <0.001 10.98 (8.34, 13.61) <0.001 
ApoB (g/L) −0.13 (−2.73, 2.48) 0.922 −0.11 (−2.72, 2.49) 0.930 −0.11 (−2.71, 2.49) 0.932 −0.11 (−2.71, 2.49) 0.933 −0.11 (−2.71, 2.50) 0.934 
Type 2 diabetes (n) −2.29 (−4.27, −0.30) 0.025 −2.28 (−4.27, −0.30) 0.025 −2.28 (−4.27, −0.30) 0.025 −2.28 (−4.27, −0.30) 0.025 −2.28 (−4.26, −0.30) 0.025 
HbA1c (%) −0.79 (−1.25, −0.33) 0.001 −0.78 (−1.26, −0.31) 0.002 −0.76 (−1.24, −0.29) 0.002 −0.75 (−1.23, −0.28) 0.003 −0.68 (−1.15, −0.21) 0.006 
Serum glucose 
(mmol/L) 
−0.52 (−0.76, −0.28) <0.001 −0.46 (−0.70, −0.22) <0.001 −0.45 (−0.69, −0.21) <0.001 −0.43 (−0.68, −0.19) <0.001 −0.40 (−0.64, −0.16) 0.002 
CRP (mg/L) −0.18 (−0.26, −0.10) <0.001 −0.26 (−0.37, −0.14) <0.001 −0.18 (−0.27, −0.10) <0.001 −0.06 (−0.16, 0.05) 0.280 −0.04 (−0.13, 0.05) 0.390 
Neopterin (nmol/L) −0.59 (−0.80, −0.38) <0.001 −0.45 (−0.70, −0.20) <0.001 −0.10 (−0.29, 0.09) 0.306 −0.00 (−0.22, 0.21) 0.976 0.11 (−0.14, 0.37) 0.375 
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Supplementary table 10. Associations between 25(OH)D levels and vitamin status and dietary data in selected quantiles of 25(OH)D levels derived from a regression 
model adjusted for age, sex, BMI, smoking habits and GFR.1 
 Quantile 
 













Vitamin D intake 
(µg/d) 
0.47 (0.36, 0.57) <0.001 0.50 (0.38, 0.61) <0.001 0.49 (0.40, 0.59) <0.001 0.42 (0.29, 0.55) <0.001 0.42 (0.27, 0.57) <0.001 
Riboflavin (µg/dL)  0.03 (−0.00, 0.07) 0.117 0.04 (0.02, 0.07) 0.002 0.03 (0.02, 0.05) <0.001 0.02 (−0.00, 0.05) 0.099 0.06 (0.01, 0.11) 0.030 
PL (nmol/L) 0.00 (−0.01, 0.01) 0.780 0.01 (−0.00, 0.02) 0.209 0.01 (0.00, 0.02) 0.018 0.01 (0.00, 0.01) 0.026 −0.00 (−0.01, 0.00) 0.830 
PLP (nmol/L) 0.01 (−0.01, 0.02) 0.354 0.03 (0.01, 0.05) 0.005 0.03 (0.02, 0.05) <0.001 0.02 (0.00, 0.04) 0.013 0.03 (0.02, 0.05) <0.001 
PA (nmol/L) −0.00 (−0.01, 0.01) 0.695 0.00 (−0.00, 0.01) 0.105 0.00 (0.00, 0.01) 0.033 0.00 (−0.00, 0.01) 0.073 0.00 (−0.02, 0.02) 0.858 
Folate (nmol/L) 0.06 (−0.00, 0.11) 0.055 0.06 (−0.00, 0.12) 0.066 0.09 (0.02, 0.16) 0.009 0.12 (0.07, 0.17) <0.001 0.10 (0.02, 0.18) 0.013 
Cobalamin (pq/mL) −0.00 (−0.01, 0.00) 0.484 0.00 (−0.00, 0.00) 0.090 0.00 (−0.00, 0.01) 0.563 0.00 (−0.00, 0.01) 0.230 0.01 (−0.00, 0.02) 0.106 
MMA (nmol/L) −2.86 (−8.81, 3.10) 0.340 −2.85 (−8.81, 3.10) 0.340 −2.85 (−8.80, 3.10) 0.341 −2.85 (−8.80, 3.10) 0.341 −2.85 (−8.80, 3.10) 0.341 
Vitamin A (µmol/L) 4.27 (3.12, 5.41) <0.001 4.28 (3.11, 5.44) <0.001 4.30 (3.14, 5.46) <0.001 4.31 (3.15, 5.47) <0.001 4.34 (3.18, 5.50) <0.001 
Vitamin E (µmol/L) 0.07 (−0.01, 0.16) 0.097 0.20 (0.10, 0.29) <0.001 0.27 (0.19, 0.34) <0.001 0.33 (0.23, 0.43) <0.001 0.39 (0.26, 0.51) <0.001 
Low fat milk 
consumption (g/day) 
−0.00 (−0.01, 0.00) 0.328 −0.00 (−0.01, 0.01) 0.869 0.00 (−0.00, 0.01) 0.575 0.00 (−0.00, 0.01) 0.834 0.00 (−0.00, 0.01) 0.538 
Egg consumption 
(g/day) 
0.01 (−0.00, 0.15) 0.245 0.08 (0.00, 0.16) 0.039 0.10 (0.03, 0.18) 0.008 0.12 (0.03, 0.22) 0.009 0.17 (0.02, 0.33) 0.025 
Fish consumption 
(g/day) 
0.03 (0.02, 0.04) <0.001 0.03 (0.01, 0.04) <0.001 0.03 (0.02, 0.05) <0.001 0.03 (0.01, 0.05) 0.001 0.02 (0.00, 0.05) 0.047 
 
1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the regression model adjusted for 
age, sex, BMI, smoking-habits and GFR. PL, Pyridoxine levels; PLP, Pyridoxal 5-phosphate; PA, 4-pyridoxic acid; MMA, methylmalonic acid. 
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Supplementary table 11. Associations between 25(OH)D levels and amino acids and amino acid metabolites in selected quantiles of 25(OH)D levels derived from a 
regression model adjusted for age, sex, BMI, smoking habits and GFR.1  
 Quantile 
 













Serine (µmol/L)  −0.07 (−0.11, −0.02) 0.003 −0.04 (−0.07, −0.01) 0.022 −0.01 (−0.04, 0.02) 0.469 0.02 (−0.02, 0.05) 0.372 0.05 (−0.01, 0.11) 0.086 
Glycine (µmol/L)  −0.01 (−0.03, 0.01) 0.156 −0.01 (−0.02, 0.00) 0.143 0.00 (−0.01, 0.01) 0.922 0.02 (0.00, 0.04) 0.013 0.03 (0.02, 0.05) <0.001 
Dmg (µmol/L) −0.21 (−0.56, 0.14) 0.239 −0.20 (−0.55, 0.16) 0.267 −0.17 (−0.53, 0.20) 0.361 −0.16 (−0.51, 0.19) 0.351 −0.15 (−0.48, 0.19) 0.381 
Sarcosine (µmol/L)  1.79 (0.61, 2.98) 0.004 1.79 (0.61, 2.98) 0.004 1.80 (0.62, 2.99) 0.004 1.82 (0.63, 3.00) 0.003 1.82 (0.64, 3.00) 0.003 
Choline (µmol/L)  0.16 (−0.18, 0.50) 0.344 0.34 (0.06, 0.62) 0.020 0.46 (0.17, 0.76) 0.003 0.51 (0.18, 0.83) 0.003 0.60 (0.22, 0.98) 0.003 
Betaine (µmol/L)  −0.02 (−0.09, 0.05) 0.623 −0.03 (−0.09, 0.03) 0.331 0.03 (−0.04, 0.09) 0.423 0.06 (0.00, 0.11) 0.039 0.06 (−0.02, 0.14) 0.162 
Methionine (µmol/L)  −0.02 (−0.13, 0.09) 0.698 0.01 (−0.08, 0.11) 0.774 0.06 (−0.04, 0.16) 0.224 0.15 (0.04, 0.26) 0.007 0.16 (0.03, 0.29) 0.018 
tHcy (µmol/L) −0.56 (−0.90 −0.22) 0.002 −0.43 (−0.62, −0.25) <0.001 −0.38 (−0.55, −0.20) <0.001 −0.21 (−0.38, −0.03) 0.021 −0.01 (−0.32, 0.30) 0.962 
tCys (µmol/L) −0.06 (−0.08, −0.04) <0.001 −0.03 (−0.05, −0.01) 0.004 −0.00 (−0.02, 0.01) 0.651 0.02 (0.00, 0.04) 0.019 0.06 (0.04, 0.08) <0.001 
           
1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the regression model adjusted for 





Supplementary table 12. Associations between 25(OH)D levels and season of study visit in selected quantiles of 25(OH)D levels derived from a regression model adjusted 
for age, sex, BMI, smoking habits and GFR. 1 
 Quantile 
 













Season 1 −8.96 (−10.6, −7.30) <0.001 −8.96 (−10.6, −7.31) <0.001 −8.96 (−10.6, −7.31) <0.001 −8.96 (−10.6, −7.30) <0.001 −8.96 (−10.6, −7.30) <0.001 
Season 2 −0.53 (−2.11, 1.06) 0.507 −0.53 (−2.11, 1.06) 0.509 −0.53 (−2.11, 1.06) 0.508 −0.53 (−2.11, 1.06) 0.507 −0.53 (−2.11, 1.06) 0.507 
Season 3 11.6 (9.70, 13.5) <0.001  11.6 (9.71, 13.5) <0.001 11.6 (9.71, 13.5) <0.001 11.6 (9.71, 13.5) <0.001 11.6 (9.71, 13.5) <0.001 
Season 4  −0.44 (−1.94, 1.07) 0.563 −0.44 (−1.94, 1.07) 0.563 −0.44 (−1.95, 1.07) 0.561 −0.44 (−1.95, 1.07) 0.561 −0.44 (−1.95, 1.07) 0.562 
           
1Values are regression coefficients (β) at each quantile of serum 25(OH)D with bootstrapped 95% confidence intervals and p-values from the regression model adjusted for 
age, sex, BMI, smoking-habits and GFR. Season 1, January-March; season 2, April-June; season 3, July-September; season 4, October-December. 
 
